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William B. Gartner
ACORN

In the weeks before the initial publication of ACORN, we met
with William B. Gartner, the Spiro Professor of Entrepreneurial
Leadership at Clemson University and the founder of ACORN to
talk about the creation of this publication.
— Ali Ferguson

William Gartner

Interviewer
Tell me a story about the startup of ACORN.
William Gartner
Well, first of all, ACORN is an ongoing effort of the
Spiro Institute for Entrepreneurial Leadership to publish
interviews of entrepreneurs telling their stories about
the creation of their businesses. I think there are many
important insights into the process of entrepreneurship that
can be gained by studying what entrepreneurs say about
their entrepreneurial efforts. Not only do these interviews
offer insights into the specific activities of how ventures are
created, they also demonstrate some of the thought processes
involved in venture creation in addition to providing
important lessons for others who want to develop their own
businesses.
ACORN is one of a number of projects supported by the
Spiro Institute for Entrepreneurial Leadership focusing on
“entrepreneurial narrative.” From an academic perspective,
the stories that entrepreneurs tell about their business
creation efforts (which is one aspect of entrepreneurial
narrative) can be analyzed in a variety of ways to understand
how individuals take ideas and transform them into
businesses. An academic label for what entrepreneurs talk
about is a “rhetoric of the future.” By “rhetoric of the future,”
I refer to how entrepreneurs talk about how things will come
into existence even when, for example in the interviews that
follow, they are asked about the past. Entrepreneurship is
forward thinking, so entrepreneurs’ talk is forward oriented
as well. What I have proposed that academic scholars do
as a way to study these stories is to develop a “science of the
imagination.” Entrepreneurs create the future by “seeing the
future in their heads” and then working to take what they
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see (however clear or fuzzy these images are) and turn them
into real things. So, we need to systematically study how the
entrepreneurial imagination works, and one of the best ways
to do this is to study what they say about how they started
their businesses.
This first issue is a collection of interviews of entrepreneurs
who have started businesses based around new technologies
at Clemson University. We have sought out a variety
of entrepreneurs who started businesses many years
ago (e.g., Dee Cross: Equitox and Jack Peck: Fox Fire,
both entrepreneurs were faculty members at Clemson),
entrepreneurs with very recent startup efforts (e.g., Matt
Geavart: Kiyatec and Elizabeth Cates: Inveca), ventures
started by an entrepreneur using Clemson technologies
(Michael Bollick: Selah Technologies) and blends of
Clemson faculty and entrepreneurs involved in venture
startups (Earl Wagener, John Ballato, and Steven Foulger:
Tetramer and Chuck Pringle, Andrew Clark, and Brent
Buckner: SensorTech). These interviews are by no means
a comprehensive list of all of the startups that have been
generated because of new technologies and entrepreneurial
efforts at Clemson University. What the interviews in
this issue reflect is a change in the overall mindset of
the University to a more entrepreneurial view of how
Clemson University can foster significant economic and
technological changes that have large impacts on South
Carolina, the United States, and the world. There is a lot
of entrepreneurial activity at Clemson University, and these
interviews reflect a part of that.
Now, as to how ACORN came into being: I actually had
the idea for something similar to ACORN when I began my
academic career at the University of Virginia in 1981. My
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initial research involved detailed interviews of entrepreneurs,
and I was struck with how much information these
interviews contained about the process of entrepreneurship.
While I was an assistant professor at the University of
Virginia, I took a number of courses in magazine and book
publishing, and I even wrote a business plan on the idea of a
business publishing entrepreneurial interviews; however, for
me, the time was not ripe for actually pursuing the idea. An
academic career involves a significant amount of scholarly
research that results in academic journal articles, so while the
idea seemed intriguing, I needed to focus on my scholarly
work in order to continue as an academic and climb the
ladder from assistant to associate to full professor. Maybe if I
had been able to “multi-task,” I could have accomplished my
scholarly activities and pursue this interview idea, but I guess
for me my scholarly efforts required my full-time attention
for a lot of years.
It was not until I came to Clemson University in 2004
that the idea of publishing interviews of entrepreneurs
became feasible. And, the feasibility of the idea came about
for a number of reasons. First, I had launched a major
international academic effort to explore entrepreneurial
narratives as a legitimate scholarly activity. So, I could
see that any efforts I put into this area could also be seen
as having some scholarly legitimacy as I moved forward.
This aspect should not be under-estimated. In a scholarly
institution like Clemson, you have to do scholarly things. It
is how the game is played. Second, I had a lot of support
from the then Dean of the College of Business and
Behavior Science at Clemson University, Bruce Yandel, who
encouraged me to dream about what I wanted to see happen
in entrepreneurial leadership at Clemson. He then helped
raise money and open doors for me in the community to
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make it so. Caron St. John, Director of the Spiro Institute,
also played a major role in supporting me by give me a lot of
freedom in my role as the Spiro Professor of Entrepreneurial
Leadership to try out new things.
By January 2007, the resources necessary to start ACORN
began to fall into place. Bruce and Caron had contacted the
Hollingsworth Foundation on my behalf, and after writing a
proposal to the Foundation, we were awarded a grant to pay
for the costs of interviewing entrepreneurs and publishing
edited transcriptions of these interviews. Around the same
time, Provost Dori Helms had initiated a university-wide
program, “Creative Inquiry,” that provided opportunities
for students to work with professors on research projects.
For me, this meant I could sponsor a small class of students
who could earn academic credit to interview entrepreneurs
and engage in analyses of these entrepreneurs’ stories. I was
very lucky that two of my best students from a Sociology
class that I taught on entrepreneurship were willing to work
with me for two semesters to interview entrepreneurs in
South Carolina. As one will see in reading these interviews,
these two students (who have now graduated from Clemson
University) are Elana Shorb and Judith Campbell. Their
names are listed as the editors of the interviews for which
they were responsible.
Our initial interview efforts focused more broadly on
technology-oriented startups in South Carolina. It was
after we had conducted a dozen or so interviews that we
realized that the initial issue of ACORN should focus
on entrepreneurs with a Clemson University technology
connection. There is strong interest nationally among
scholars and policy makers regarding the role of universities
in technology commercialization. I think these interviews
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add to this discussion by portraying the critical role of
entrepreneurship in commercializing technologies. So, over
the past two years I have worked with a number of students
in my Creative Inquiry course (entitled: Entrepreneurial
Narrative) to interview entrepreneurs about their business
startups.
Now, while one part of the equation was solved by
interviewing entrepreneurs, another critical aspect of
developing ACORN needed to be solved: actually publishing
the interviews. A lot of work has been undertaken in order
for ACORN to be published in the form you see here. For
example, transcriptions of the interviews needed to be fine
tuned (which meant working with the entrepreneurs on their
transcription revisions until they were satisfied with their
stories), a layout design for ACORN needed to be created,
interviews had to put into this layout format (as you see
here), photographs of the entrepreneurs needed to be taken,
a printer needed to be found, the work to print ACORN
needed to be coordinated, and ACORN had to be put on
the Spiro Institute website, as well. A thousand different
details that, frankly, I am not talented or skilled enough
to carry out. All of these critical tasks were undertaken
by Ali Ferguson, who became involved with this project
in July, 2009. Ali graduated from the Master’s of Arts in
Professional Communication program at Clemson University
in August and has been willing to work full time for me
now on the publication of ACORN. Without her efforts at
managing all of the details of the publishing process over
the past three months, there would not be an ACORN.
One of the academic words for how the process of starting
an entrepreneurial company actually comes together is
“bricolage.” Entrepreneurs invariably need to “take what
they can find at hand” (which is bricolage’s definition) and
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use these resources to create the business. Ali has proven
to be an innovative “bricolager” at finding and using our
limited budget to bring ACORN into being.
The story of ACORN really involves a lot of other people,
besides me, who enabled this publication to exist. I suppose,
that would make for an interesting issue of ACORN: What
if all of the people involved in the startup of a particular
business were to tell their stories: the entrepreneurs,
investors, employees, suppliers, buyers, and “significant
others”)? Wouldn’t that be interesting to study?
Interviewer
One question: Why title the publication ACORN? There
seems to be a lot of controversy about the name “acorn”
since, for some people, the word is associated with the
organization ACORN (Association of Community
Organizations for Reform Now).
William Gartner
Well, for me, entrepreneurship has always been about this
saying: “from little acorns great oak tress grow.” I think the
oak tree analogy is very germane to creating and building
businesses and for economic development. When we see a
large business, we need to realize that it originally started
small, just like an acorn. There are only a few exceptions
to this. And, for every oak tree that grows large, there are
thousands of acorns that tried to become oak trees and
failed. For me, that is the critical insight for business and
economic development: we all want oak trees, but, oak trees
begin as acorns, so, you start there, with the acorn.
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Jack Peck
Foxﬁre Technologies Corporation
& FastFetch Corporation

Jack Peck has founded a number of different companies during his
career. This interview focuses on two of these companies: Foxfire
Technologies Corporation and FastFetch Corporation. Foxfire
creates and sells software and hardware that collects data in real
time on the manufacturing shop floor for sewing activities as well
as software for managing the productivity of warehouses. Jack
sold this company in 2006. He then started a new company,
FastFetch. FastFetch is a patented order fulfillment system
built around a Personal Digital Assistant (PDA) that uses a
combination of light directed picking, voice picking, and wireless
scan picking technologies. This interview was conducted in
October 2007 during a class on entrepreneur-ship at Clemson
University. Since this interview, FastFetch has merged with a
much larger, more established company, Wesley International, to
form a new company called Wesley/FastFetch LLC, doing business
as “Alexa.” Alexa had a major roll-out of products at the Promat
Show in Chicago and the National Retail Federation Show in
New York City in January 2009.
— Elena Shorb

Jack Peck

Jack Peck
I was asked to come and tell you a little bit about some of the
experiences that I have had with my company, Foxfire, which
I started 20 years ago, but before I do that, I want to go over
some of the other companies that I helped start. I have been
involved in some companies that have had successes and
some companies that have had failures. It is a lot easier to
have failures, by the way, in case you are out to do one or the
other. But oftentimes there are good lessons to be learned
through the failures. I guess I always had an entrepreneurial
spirit. It is easier to look back and figure these things out
now than it was at the time.
My first entrepreneurial venture happened while I was
attending graduate school in Louisiana. I was approached
by two people that were about 10 or 15 years older than me,
who had decided to start a company, and they asked me if I
would join them. We started a company for which I was the
technical resource and they were the experts in running the
business. The others were both CPAs.
We were putting together computer systems in a company
called TECH Data Systems: Technical Engineering
Commercial and Hospital Data Systems. I was developing
software in all of those areas. The company only survived
for a little over a year before it was shut down because of
illegal activities. The two CPAs were running payrolls for
hospitals and other groups. They would print out a stack of
checks for a hospital’s payroll system and would hand the
checks to the hospital saying, “Okay, give us the amount of
money equal to all of these checks,” and the checks would
then be drawn against a common account for all customers.
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Well that sounded like a reasonable way to do things. The
problem was that the CPAs were spending some of the
money out of that account before the checks cleared. Banks
do that all the time, even today, but the problem was that
they did not put the money back. So they would have to run
another payroll before the last checks cleared, which made
them bounce for insufficient funds. They would have to run
another payroll to cover deficits from the previous payroll,
and the problem would keep being pushed into the future.
They would do this using more than one bank account.
Today, we call that “check kiting,” which is illegal.
I did not know this was going on. I was too busy writing the
programs and making sure they all ran smoothly. I learned
an important lesson: if you do not understand what is going
on and you ask people to explain it to you but they cannot
explain it to where you can understand it, maybe they are not
telling you all the facts. You need to understand everything
going on in your business. I learned that lesson pretty
quickly.
After that venture ended, I finished graduate school and
came to Clemson University. I am on the faculty in the
Computer Science Department as an emeritus professor. I
started a group at the university that is still ongoing called
The Division of Information Systems Development. This
group does a lot of contract work for the state. I ran that
group for about four or five years, and it still exists today.
We were doing work for about 25 different state agencies
from the governor’s office down to Lander College. At about
this time was when I started my next company called Series
One Incorporated, which ended in failure. IBM, at the time,
had a machine called a System 32, which became a System
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36, which became a System 38, and then went on to bigger
and better things. The System 32 was their commercial data
processing machine, which many smaller businesses were
using. They also had another machine called the Series One,
which was a process control computer. Its main functions
were scientific and engineering applications. We discovered
that the Series One had a lot of power, but it did not have
the same software as the System 32. Nevertheless, the Series
One was a lot cheaper and a lot more powerful.
So several of my friends and I got together and wrote an
entire operating system, the System 32 Operating System
and made it run on the Series One. We also wrote an RPG
compiler and all of the rest of the software that had to go
on it so the Series One looked like a System 32. It really
ran quite well. We had investors in our company, Venture
capitalists if you will. We did not get a lot of money, but
it was enough to keep us going. We got a Small Business
Administration (SBA) loan through a bank in Greenville.
Then I found out that there was some behind-the-scenes
dealing again. I had no idea it was going on until it was too
late. As it worked out, the bank had made an investment
in another company (with partial ownership by a relative of
a bank executive) that was about to go belly up. The bank
then sold all of the assets of that company to Series One (as
authorized by the Series One president who we discovered
had interests in the failing company). This in turn drained
all of the SBA resources away from us. We had no money
to operate and had a bunch of obsolete assets that we could
not use. So, again I learned that even if the technical side
is going well, the business side of it can kill you if it is not
done with proper controls. So, I got out of that one. That
business only cost me about four months of salary.
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I next started another business here in Clemson called InfoData Business Systems. That one did not have any crooks
in it, fortunately, but it was ahead of its time. The business
was doing things that became popular about 10 years later.
The idea was to take small computers and move them into
standard business applications. Most businesses really were
not ready for small computers just yet.
Small computers, like the Radio Shack TRS 80, were more
of a hobbyist thing rather than tools for running businesses.
It was back in the old CPM days for those of you who may
have studied a little history. In any event, that company was
a little ahead of its time, so the lesson we learned was that
timing is pretty important. You can have good ideas and bad
ideas, but timing, getting these ideas into the market at the
right time, is something that I learned from that experience.
I started another company after that called Apparel Soft.
That failed, but I will not spend any time telling you about
that. Finally, I started a company for which I took all of
my previous experiences into consideration and said, “I am
going to start a company in which I know what is going on,
and if it fails it will be because of my failures, not someone
else’s.” I was a major player rather than a minor player. I
started it with another gentleman who now lives in Marietta,
Georgia, and our company was named Foxfire Technologies
Corporation, which started in 1987.
We had an idea for a product, mostly software and some
hardware we purchased from another company. Foxfire
started with two of us (actually three of us, but we bought
out the other person) pretty much in my garage. Some
people say, “Well why did you call it Foxfire?” Does anyone
know what Foxfire is? It is a fungus that grows on dead
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trees. Some people would say we named the company after a
fungus, but that is not quite the way we did it. If you go back
to the roots of the term Foxfire, you will learn that it exists
in the woods in the southeastern part of the United States.
The best place to find foxfire is in the mountains. If you find
an old stump or an old pine tree and you kick it over, when
the inside of the stump is exposed, there is a mold that grows
inside. At night, the mold glows. Foxfire is the local term for
the glowing fungus.
There was a fellow named Eliot Wigginton that taught
English in a high school in northern Georgia. He had his
students interview people up in the mountains—the old
timers—about how they did things. There is a series of books
now, about 12 or 13 books, called the Foxfire books. They
are a collection of chapters with directions on how to make
dulcimers and soap and a lot of other things.
We did not name our company after these books either. In
reality, we were sitting around one day trying to figure out
what to call the company, and we happened to be meeting
in an apartment complex in Seneca, SC. The complex was
named The Foxfire Apartments. We argued and nobody
could agree on a name. So we just threw our arms up and
said, “We should just name it Foxfire after the apartments
where we are meeting.” So, we were named after an
apartment building complex. It is a catchy name, and people
have generally heard the word Foxfire in this part of the
country. But, Foxfire often gets confused with Firefox, the
Internet browser.
When we started Foxfire we got our first contract with
a company called Tultex, a large apparel manufacturing
company in Martinsville, Virginia. Our software product
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collects data on the manufacturing shop floor, in real time,
for sewing activities. At one point, Tultex had around
10,000 employees. In some of the plants they had about
2,000 people sewing in one great big building. I do not mean
to tell you too much about apparel manufacturing but a little
might be helpful in terms of understanding the complexity of
an apparel operation and the problem we were solving.
To make a shirt, there are approximately 40 operations
to be carried out. Some of them include sewing the hem,
sewing the buttonholes, sewing on the buttons, setting
the sleeves, etc. First the shirt fabric is cut; then multiple
plies of material are laid out, typically about 40 plies high.
A reciprocating knife cuts out each piece (the sleeves, the
fronts, and the backs), and the pieces are all placed into
stacks. There are stacks of 40 collars, 40 sleeves, 40 fronts,
etc. The stacks move through the sewing floor in parallel.
One collection of people work on the sleeves, another
collection of people work on the fronts, and so on.
Typically there are about 10 to 15 garment subassemblies
traveling independently through the sewing floor, and
they have to come together for final assembly to become
a finished product at some point. The aim of the Foxfire
software is to make sure that the sleeves are moving at the
same rate as the collars and the fronts. This way they will all
come together at the same time for final assembly.
This is a non-trivial task, particularly when you have 2,000
people sewing on different stacks of subassemblies all over
the factory. Typically, we have about 200,000 to 300,000
work-in-progress units going at the same time, and keeping
track of all of this is very important. Also, keeping track
of the efficiencies of the employees is necessary because
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these people are paid by piece work. The Foxfire software
increased the productivity of employees between 15% and
25%, representing a lot of savings. We installed the Foxfire
software system in many other companies including Brooks
Brothers, Wrangler, and Levis Straus.
Interviewer
Why did you choose the apparel industry?
Jack Peck
I started the company back in 1987 while working as a
faculty member at Clemson. As a professor you experience
forced unemployment during the summers. Well what kind
of industry did we have in the SC Upstate back in 1987?
Textiles and apparel companies were predominant. Textile
people make the cloth, while apparel people sew the cloth
together into garments, seat covers, clothing etc.
The original Foxfire software was a fairly complex system,
and it is still being run offshore in places like El Salvador
and Mexico. Most of the textile and apparel industries have
moved offshore in recent years. I have spent a lot of time in
El Salvador installing and training people on the software.
So the system is multilingual, and right now, we are looking
to move it into the Far East (China) because that is where the
apparel industry has gone.
Interviewer
How did you come up with the idea for this real-time system?
Jack Peck
I had done consulting during the summers with some
industrial engineers who were in apparel manufacturing. I
went into plants with them and just watched what they were

ACORN 17

doing and thought, “Man, there has got to be a better way.”
When I saw how they were collecting the data, it seemed very
inefficient to me.
For instance, if I am the person sewing the collar, attached
to the collar is what they call a “gum sheet.” A gum sheet
is a collection of coupons. Each coupon represents an
operation that has to be carried out on each bundle of parts.
The employee takes the coupon and sticks it onto a sheet
of paper, which marks the task as completed. Every time
you complete a task you have to make a record of what you
have done so you can be paid accordingly. The clerical work
involved with the coupons took up about 20 seconds for
every single bundle, and workers might complete around
100 bundles per day. The coupon system is inefficient
because you are paying employees for clerical work rather
than sewing. So I said to the engineers, “If we can cut down
on that clerical work and reduce it from 20 seconds to two
seconds, it will result in a huge savings in terms of labor
increased productivity.”
Our system became very popular. It was a little more
difficult to market a system like this offshore simply because
the labor rates are lower. They’ll just say, “Okay, so what
if it takes 20 seconds more? I am only paying $0.50 an
hour.” There is a lot less incentive for them to become more
efficient.
We eventually started to look at logistics to see if there
were any opportunities in that area. This was when we
started creating a warehouse management system. The
way warehouses operate seems rather mundane. You take
something off of a shelf, you put it in a package, and you
mail it. However, there is a lot more to it than that.
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One of Foxfire’s biggest customers is Alltel Communications.
Alltel has approximately 3,000 stores across the country all
of which are shipping orders late in the day while expecting
them to be delivered next day via UPS. In order to fill all
of the orders quickly and accurately in a short timeframe
is very difficult. When we originally went into Alltel, the
warehouse was a complete mess.
We implemented our system into their warehouse and
smoothed out their operation considerably. With their old
system, Alltel was running three shifts seven days a week
and still were not getting their work out. They were working
people overtime and incurring a lot of extra costs. Today,
they are shipping twice the volume and are only running one
shift five days a week. You can see the kind of savings that
they are looking at on labor, customer satisfaction, as well as
many other aspects that are byproducts of doing a better job.
Interviewer
How did you integrate your software with what they already
had in place?
Jack Peck
We replaced what they had. We did have to do some
integration because there are things that Foxfire’s software
does not do. For example we do not have an order entry
system. Their ERP (enterprise resource planning system),
which addressed their accounting issues, order entry, and
billing, was already in place. So, we had to interface with
their ERP. When an order comes in, we pick it, get it packed,
and ship it. The transaction transfers back up to their
corporate computer that says, “You need to bill these folks
because here is what we just sent them.” There is a fairly
clean interface.
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Orders come down, and information goes back up. Of
course it is a little more complicated when an order from
a supplier is received because we have to know that it is
received. We have to put the inventory away, know where
we put it, and be able to call for it when the time comes.
There are perishable issues for some products, so you want
to get rid of the oldest first. There is replenishment; there is
consolidation.
The Foxfire manufacturing systems are still being sold, but,
in the United States, the only customers who are buying
and operating this system are a protected species called
“government contractors.” There is a law called The Berry
Amendment that says all sewn products for our military
must be made and purchased in this country if they are at all
available.
Right now, Foxfire software controls the manufacturing
process for 100% of the chemical protective suits made
for our military. The chemical protective suits are a little
different from your standard shirt or pair of socks in that you
have to have a complete pedigree for the product. If there is a
problem down in the field with the garment, we have to trace
it back to what sewing machine sewed it, what raw materials
went into it, who was running that sewing machine precisely
when it was made, and what kind of thread was used. After
that we have to go forward to see what other products were
made using that sewing machine, which person was sewing
on that machine, etc.
One of the most important things that I learned from
Foxfire was that when we started to get key employees, we
needed to give them some interest in the company. We felt
it was important that they be invested in and dedicated to
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the company. The second thing was that the two of us who
started the company had an agreement that we would receive
the same compensation out of the company independent of
who did what. That way we would not look at each other
and say, “Well I did a little more than you last month, so
I ought to get a little more than you do.” We just said,
“Okay, we are all going to do what is required, and whatever
compensation one gets, the other gets.”
My partner was full time and I was part time. At the time,
I was teaching at Clemson and continued there until
2000 when I retired. One of the reasons that I formed the
company was to be able to put my kids through college. At
one time, I had my wife and three kids going to college at
the same time. The sum of the tuitions exceeded my takehome pay from the university, so I had to have some outside
income.
In any event, my partner was working full time at Foxfire,
and I was working at Clemson. So, we took my Clemson
compensation and my compensation with Foxfire and
made it collectively equal to his compensation with Foxfire.
This worked out really well for us since no one complained
that one person was doing more work than the other. My
partner’s specialty was not technology related; rather, his
specialty was in the business aspect of things. He has a
Master’s of Business Administration, so his background was
more in the financial side and mine was in the technical side.
We always kept an eye on each other, too.
Interviewer
How big did the company get, and how big is it now?
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Jack Peck
The largest we got was about 40 employees in the United
States, but, overall, we had 50 employees because we opened
an office in India. I failed to mention that. Back in the
dot-com era, when the dot-com growth was really heading
sky high, it was tough to get good technical people. We could
not hire them because they were all moving to California to
become wealthy, my son included. So it was difficult to get
good people.
One of the people we hired was actually a former student
of mine, an Indian student who had good connections in
India. We opened an office in India to start development.
That office is still doing development for us today. We have a
decent number of people in the states as well.
U.S. employees design the software, ship it off to India to get
the initial implementation done, get it back from India, make
sure that it is done the way that it was supposed to be, kick
the tires, fix any problems, and finally install it at customer
sites. We felt like it was important to have maintenance
and support going on in the United States versus in India.
If someone says, “My warehouse is down. I cannot ship
my product,” we put somebody on an airplane, and within
four or five hours, he/she is there on-site trying to fix the
problem. We do not do this very much, but it makes our
customers feel that, if necessary, we can do that. It is a little
tough to do that from other countries.
Foxfire is now a growing company with new owners. The
new owners of Foxfire had been chasing us for a while. They
are former Datastreamers. Datastream was a company in
Greenville that was bought out by a company called Infor
about two years ago. One of the Datastream owners, a man
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named John Sterling, had a non-compete for a year. So,
after a year he jumped in and bought Foxfire and is going
to do with Foxfire what he did with Datastream. He took
Datastream from $600,000 a year gross sales to over $100
million a year. He sold Datastream for $224 million. His idea
is to again take a small company and build it up.
Interviewer
Did your partner stay with you the entire time?
Jack Peck
Yes. We are still partners in our new venture. We stayed
together for 20 years while Foxfire grew. We sold in 2007.
Interviewer
What kept you together for 20 years?
Jack Peck
Well, we kept making money. We kind of liked that. We
never operated in the red from the day we opened the
door. We treated our employees’ right as far as benefits
were concerned. We had hospitalization and dental. We
paid 100% of the premiums on all of those benefits, and
we had really good policies. We had what is called an SEP:
Simplified Employee Pension plan, which is like a 401K.
We fully funded every year since we started it, which was
the whole history of the company. The employees made
no contribution. We gave bonuses at the end of each year
depending on how well the company did. In some cases the
bonuses were greater than their annual salaries. We treated
our employees right, and we had very, very little turnover as
you might imagine.
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Interviewer
Did you and your partner get into any conflicts, and if so,
how did you resolve those issues?
Jack Peck
We took a vote, and I always won. No, we did have some
differences of opinion. You are always going to have
differences. I gave in sometimes, and he gave in sometimes
depending on the nature of what we were talking about. We
rarely compromised in the sense that we took the middle
ground between two positions. Sometimes that does not
work very well.
If it was something that was more business related. I just
let him have his way. If it was related to how we were going
to spend money, if we were going to hire another technical
person, who we should hire, etc., he pretty much relied on
me and my technical expertise in that area.
Interviewer
I am very interested in the sequence of actions during the
initial stage of creating Foxfire. Did you form the company
before you had your first sale? How did that work? When
did you have your “first sale,” and when did you start
development?
Jack Peck
We had a contract in hand, and then we formed our
company. Our customer, Tultex, was contracting with me, as
an individual, for this product. They said, “Go ahead and do
it.” So we said, “Let’s draw up the document, the contract,
precisely describing what we are going to deliver, how much
it is going to cost, how long it is going to take, etc.” We drew
it up, and then we formed the company. Then, that contract
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was assigned to the company because we felt it was important
to have some sort of protection.
Interviewer
What do you feel brought them to the table as you were
negotiating the contract?
Jack Peck
What convinced them to do business with us? The idea.
This was an idea they had been asking themselves about:
“How can we cut costs and increase production; how can we
do it?” We told them how we could do it, which they had
never considered. They said, “Well these guys are pretty
creative and pretty bright, so let’s take a chance on them,”
and it worked out fine for everybody.
Interviewer
What kind of capital did you use to start the company?
Jack Peck
Nights, weekends, and sweat equity. We had no capital. We
drove our own cars, we paid for our own gas, and we took
no money in terms of salary. I had a PC, a little bit of time,
some development software, and that was all.
After we delivered our first product and we had a showplace
we could take people to, we started getting a lot more
business. Then we asked ourselves how we were going
to market because the first time we had sold before we
developed. At the time, we had an offer from a venture
capitalist to put some money in. He wanted a big hunk
of the action, and we decided that we would not go that
direction. We decided to grow more slowly with less money
rather than faster with more money.
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So that may have been a bad decision. I am not claiming
that it was the right decision. That was just the decision we
made. In fact I suspect that, particularly when it came to the
warehouse management side of the business, we actually had
products before any of our competition. They beat our pants
off, though, because their companies grew faster with more
capital.
They grew a lot faster and a lot bigger. The guy that I knew
who started Manhattan Associates sold his interest for $400
million when he cashed out. He did pretty well. He took
the venture money and grew faster, and that was a better
decision. I will have to give him that.
In any event, those are choices you need to make, go slowly
and maintain more of the company or grow faster and give
away part of it. There is no right answer. There is just a
thoughtful answer. We are growing slowly right now with
my new company, but that could change.
Interviewer
When you made your first contract, it appears that you
arranged, as part of the deal, that you would develop the
product for Tultex, but you still had the rights to it, and you
could sell the product to other companies.
Jack Peck
Yes, that was known right up front. We were not just
consultants for hire. We were developing products that we
would own, and they would buy licenses to. We gave them a
really good price, as you might imagine, because of that. We
did not sell products; we sold licenses to products. Obviously,
if you sell a product to someone, they own it and can do
what they want with it. So we sold the license to the product
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and the support services. We also ended up selling a lot of
media, i.e., paper.
When the company ships products from their warehouses,
they have to put little labels on them that says where they
will go, the shipping labels. You would be surprised how
much money there is in shipping labels. If you can make a
nickel on each one it really adds up. So we would go into a
company and say, “Our normal license fee is $96,000.00 for
this software. We will give you a 50% discount if you will
agree to buy the media from us.” They have to buy it from
somebody, so why not us, right?
They would jump on that, and it ends up being an annuity
for us that they pay year after year. It does not take long
before it exceeds the $48,000.00 discount that was given to
them. This was not my idea; this was my partner’s idea. A
lot of companies like to do things this way because shipping
costs are coming out of a different budget.
Interviewer
Why did you sell Foxfire?
Jack Peck
I mentioned one of the reasons, money. The other reason
was FastFetch, my current company. I had an idea walking
through a bunch of warehouses and seeing how people were
doing things.
Interviewer
How did you come up with the name FastFetch?
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Jack Peck
We tried to have catchy words, and with Foxfire, I had an
idea when I was Chairman of the Board. Let me tell you a
little about the idea behind FastFetch before I answer your
question about the origin of the name.
My idea was to figure out how to fix things in warehouses
as far as picking, shipping, and other operations. An order
comes in, and you have to get all of the inventory items
together, put them in a box, and ship it. That picking
process is where more labor is spent in a warehouse than
any other place. A lot of the big retailers like Walmart and
Target will charge you a lot of money if you do not ship them
precisely what they ordered. These penalties are known as
“charge backs.” They will charge you back a lot of money for
doing it wrong.
Sometimes the charge back exceeds the cost of the
merchandise that you sent them. In this case, they will
deduct the charge back from your bill before paying it. There
are many companies that are very sensitive to charge backs,
as it costs them millions of dollars a year. So, when you say,
“I can show you how to pick your product three times faster
with 100% accuracy,” you get their attention. I figured out
how we could develop technology that will allow you to do
just that: pick about three times faster with 100% accuracy.
So, I applied for a patent on it, and as soon as the patent was
granted, we began development.
We did not want to start development until we knew we had
patent protection. When we started development on the
product, the entire project was funded by Foxfire because
development was happening inside of Foxfire. One of the
people who I called in to help on the project was Ed Page.
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He used to have an office right above this classroom (in
Brackett Hall). He was previously the Director of Technology
Transfer, and he was the head of the Clemson University
Research Foundation. About a year ago, he retired from
Clemson and joined me at FastFetch. Ed and I were also
colleagues in the Computer Science Department.
Ed came in and we worked on the development of software
as well as hardware. We developed and designed a lot
of hardware and prototyped it. Ed was not an owner of
Foxfire, but he was a strong participant in FastFetch, the
new company. At that time, it was not called FastFetch: our
product was called FoxFetch. FoxFetch is “fetching” stuff,
meaning picking. We showed the technology at a trade show
and got a good reception.
We thought our product had the potential to take off.
FoxFetch, as a product, had no history of sales. We had been
developing, getting patents and intellectual property, doing
designs and prototypes, and arranging for manufacturing in
China. FoxFetch had been nothing but a drain of resources.
We worried that when someone eventually came in to buy
Foxfire, whether they were going to value the FoxFetch
product at zero or even a negative value since there was no
history of sales. We decided to move the FoxFetch product
into another company. We ended up naming the company
FastFetch. We did not want to call it FoxFetch because this
product not only runs with Foxfire software, but it also runs
with all of Foxfire’s competitors’ software. It is an adjunct
to a warehouse management system. So, we did not think
our competitors in the warehouse management system arena
would be too happy about sending their customers to deal
with one of their competitors. We wanted to completely
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separate this product from Foxfire to avoid conflicts, and it
has worked out really well for us.
We formed the new company, and gave Ed 25% of it. The
other Foxfire shareholders got the other 75% collectively, in
proportion to their ownership in Foxfire. This included some
of the employees who had a stake in Foxfire at the time. It
was a good way to do it, and everyone was pleased. FastFetch
was then formed in August 2006 and is a little over a year
old now. We have had some very good press and were picked
as one of the eight most innovative products of the year in
warehouse management systems.
We have had some reviews by some of the major companies.
You have probably heard of Gartner and Forester Research.
There is another company called Aberdeen Research with
the Aberdeen Group. They did a review and had a very nice
report of our product. We did a head-to-head test against
Levi Straus’ best system for picking in a warehouse and beat
them three to one in picking efficiency with 100% accuracy.
We have been very pleased with our progress to date. We
have two customers now, one of them is a company called
A Beka Book. I do not know if any of you have heard of A
Beka Book, but they are the largest publisher of Christianbased, home school, and educational materials in the world.
They are located in Pensacola, Florida. A Beka Book is part
of the Pensacola Christian College. They are actually the
major source of money for Pensacola Christian College. All
the profits from A Beka Book help fund the school. Instead
of state appropriations, they have their own publishing
company.
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Interviewer
Is your software web based or is it non-web based?
Jack Peck
In terms of Foxfire, we have some Web- and some non-Webbased software. It is not an issue of what works best and
makes sense. The problem with the Web is that you cannot
process 100 transactions a second, but you can with a local
area network. We are very sensitive to the real-time aspects
of operations. Typically, the software is not Web based.
Interviewer
What business problems does FastFetch solve?
Jack Peck
Imagine a warehouse. A warehouse has racks and bays with
products that are on shelves. Pickers walk through with an
order and pick out the products they need to fill the order.
They walk through the warehouse, generally with a cart or a
tote, and put the products into an order box. It takes a long
time to be able to pick more than one order at a time. We
call that batch picking: multiple-order picking.
So, with FastFetch we put order boxes on the cart, we get a
download of orders consistent with the capacity of the cart,
for example 10 orders, into a PDA. The entire system runs
on a Personal Digital Assistant (PDA). We developed some
hardware that allows us to link the PDAs to lighted numeric
displays (lights). One lighted display sits under each order on
the cart.
The PDA verbally tells the picker where to go, what to pick,
and how many of each item to pick. If you have a cart with
10 order boxes, there will be 10 lights. If you have a cart
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with 200 orders, you have 200 lights, one sitting underneath
each order box on the cart. Similarly, at each bay location
we have a lighted numeric display. When you push your cart
down the aisle, it tells your PDA where to go first. There is
an infrared signal sent from each PDA that “polls” for the
bay to pick from.
When the picker reaches the right the bay, the PDA says,
“Stop,” using a combination of voice and visual prompts.
The PDA sends the signal out to the bay and lights up the
numeric displays (with a “5,” for exampe) where you need to
pick. It will say, “Take five of that item.” When you look
over at the cart, there may be lights under two boxes: one
with a two and one with a three both of which are lit up.
So, the first order needs two of those five products, and the
second order needs three of them. This is called cluster
picking. The system allows workers to pick very quickly with
no paper. It tells you verbally where to go and when to stop.
If you go to www.FastFetch.biz there is a video you can look
at of the system in operation. It is about 14 minutes long,
and it tells you a lot about the system in greater detail.
Interviewer
Does the system require a lighted numeric display under each
product in the warehouse?
Jack Peck
Well that is a good question. First of all, there is one other
feature of FastFetch that helps lower cost. If you pick a
certain product once a year you probably cannot afford to
put a light on that location. That is pretty clear. So, what we
have done is to integrate a Bluetooth scanner and a barcode
scanner. If it directs you to a location where it knows there
is no light, it will tell you verbally to go over and scan the
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barcode on the product. At that point, you have confirmed
that you are at the right spot. It then tells you verbally to
pick a certain amount, for example “three.” You grab three,
turn around to the cart, and the lights on the cart tell you
which cart location (order) to put them in. Abeka Book, in
their first phase of installation, had no lights on their bays.
The only lights were the ones on the carts. They were using
Bluetooth scanning to confirm that their workers were at
the right bays. The Bluetooth signal is not as fast as the light
calling your attention to the bay. Most people use what is
often called the 80/20 rule: you put lights in 20% of the
products that generally represents about 80% of your picking.
So, about one-fifth of the cost buys you 80% of the benefits.
Interviewer
Are you competing against companies that are developing
their own systems, like Amazon?
Jack Peck
Amazon and some of the others are using several different
methods. Let me talk about the competing technology,
which companies like Amazon use. Competing technologies
are, of course, mostly paper, which is not a terribly
competitive technology. Another technology is carousels.
Carousels have locations that rotate. When you say, “I need
something,” it rotates until the item you need is presented.
However, it can take up to a minute for the carousel to
present the product to you, which can be a very inefficient
and time consuming.
Interviewer
What do companies like Walgreens use?
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Jack Peck
Walgreens uses some carousels as well as other things too,
but the advantage of carousels is that they do not take up a
lot of floor space. You do not need the extra space to be able
to walk between aisles.
Another technology is radio frequency (RF) picking. With
RF picking, there is typically a portable handheld barcode
scanner that receives a radio signal and tells you where to go
on a little screen. It reads something like “Go to location
R-15-023-014.” When you get there, you have to scan either
the product or the location barcode, which is very similar to
what we were talking about earlier. Typically you are doing
a single order at a time. You scan the product, put it into a
box, scan another one, put it into the box, and so on. Most
companies that use RF picking do not do multiple-order
picking. It is very slow to make a trip through the warehouse
for every order; it can take you up at an hour to fill an order,
particularly if you have a large warehouse.
We have developed special optimization techniques using
what we call genetic algorithms. I do not know if you have
heard of that term, but they borrow from the principles
of biology. Say you have 200 orders. If your cart has the
capacity for six orders, then you ask: “I wonder which six
orders (out of perhaps several hundred possible orders) I
ought to put on this cart. I would like to fill similar orders
at the same time, so I will not have to walk too far in the
warehouse.” So how do you determine which six orders are
the best in terms of minimizing the travel time through the
warehouse? It is a tough problem. It is what we call an NPcomplete problem in computer science terms, meaning that
the time to solve it is not proportional to any polynomial
function. We have developed some very clever algorithms to
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do that. It is fun taking some of the concepts pertaining to
computer science and actually putting them into action by
building products.
Other types of technology you see in picking are pick-to-light
systems. They are similar to what I was talking about with
FastFetch. The biggest difference is that the lights are only
on the bays, not on the carts. So you are typically doing one
order at a time and have an automated conveyor delivering
the boxes from one place to another. The problem with
this is that you can only pick one order at a time. Also there
is a central computer in the back room that controls all of
the lights in the entire warehouse. Your first light with that
system typically costs you about $150,000; whereas, our first
light costs $50.00. So you can see that we are into an area of
the marketplace where we are very competitively priced. We
do not have the big infrastructure that you have with pick-tolight systems.
There are a few other types of picking technologies. There
are products called A-frames that are really high speed, but
we are not competing with those. They are primarily used
for drug wholesalers or cosmetic supply companies like Avon.
It is called an A-frame because the picking device looks like
an A-frame house. A conveyor runs down the center of
this big A-frame; there is a box on the conveyor, and as it
moves through the A-frame, it shoots out all of the ordered
products into the box. It is highly automated.
I mentioned earlier that we currently have two customers.
The second customer is a company called GENCO, which
is in Pittsburgh. GENCO is the third largest third-party
logistics company in the United States. A third-party
logistics company is a company that runs warehouses for
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other people. The products in their warehouses do not
belong to them; they just run the warehouse for a different
company. They put the stuff in the warehouse, take it out,
pick it, pack it, ship it, and provide the labor. Sometimes,
they own the physical building, and sometimes they do not.
GENCO is very large and is right behind UPS and FedEx in
terms of size. They did a test of our system and had a thirdparty industrial engineering company come in to monitor
the test. They used their own system that they produced
internally, and we beat them three to one. They are going to
be putting our system into many of the warehouses that they
run around the country. We are looking forward to that.
In terms of the development of the business, right now
we are part the SC Launch! program, a program which is
administered by the South Carolina Research Authority.
What they are trying to do is help entrepreneurs who have
good ideas start companies in South Carolina. In order
to become part of that program, there is a fairly involved
questionnaire. There is also a multi-page document that you
have to fill out explaining your business plan.
That gets you into the program, and with that, you get a
network of people who can help you. The second part, if
you are interested in continuing, is to get some initial capital.
You can get up to $200,000 from SC Launch! in the form
of a loan. Like all loans, you are expected to pay it back;
however, the difference between this loan and a loan from
a bank is collateral. You do not put your personal assets on
line with SC Launch!, as you would with a bank.
Now if you cannot pay the loan back, SC Launch! takes part
of your company. They will take interest in your company,
a percentage, which is determined by different factors
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depending on how well you are doing at the end of the
period. At this point, we have filled out all the applications
and are in the process of going through what they call “due
diligence” with the SC Launch! program. We are hoping to
become part of that program and get additional funding.
We were recently nominated by a group called Innovision in
the Upstate to receive an award. Innovision is a group that
fosters and promotes the development of technology. There
are big companies like Michelin, BMW, and Fuji as well as
few small companies like FastFetch. We were selected by the
Innovision group as one of the three finalists to receive an
award. In November, we will find out the results, but it is an
honor to be one of the final three.
I might say that the FastFetch product is also good for
companies similar to BMW suppliers. Within a 20-mile
radius of their plant in Spartanburg, BMW has about 85
different suppliers. BMW gives them an electronic order, and
within two hours, they are expected to have materials at the
BMW headquarters ready for the production line.
For instance, say that BMW plans to assemble 300 cars.
If I am the wiring harness supplier, they will send me an
electronic order for 300 wiring harnesses all of which could
be different. The pickers must very quickly and accurately
pick the correct wiring harnesses. The added complexity of
the BMW picking problem is sequencing the picked items
onto the cart. The first position on the cart must have the
wiring harness for the first car; the second position must
have the wiring harness for the second car and so on. Not
only do the workers have to pick quickly and accurately, but
they have to sequence them onto the cart in the same order
as the production line.
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That is a tough problem for people to do in two hours. Our
technology will do that very quickly too because it lights the
light on the cart, which tells precisely which location to put
the picked item for each particular car. We are targeting that
marketplace as well as anybody who does replenishment:
convenience stores, pharmaceuticals, auto parts suppliers, or
anyone who takes point of sale data or customer orders that
come in very quickly. That is the target market that we are
looking to be involved with, and there seems to be a lot of
companies in it. We are very excited about the future. My
plan, if everything works out, is to build the company for
about three to five years and then sell it to a larger company.
At Clemson there is PTR: Post Tenure Review, a process I
went through when I was a Department Chair. PTR forces
the University to examine the tenured faculty periodically to
make sure they are all productive. We were joking the other
day and saying if they start a PRR, Post Retirement Review,
process, I am in trouble. I have not been doing it properly,
but it has been a lot of fun.
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Dee L. Cross
Equi-Tox Pharmaceutical
Research and Development

Dee Cross is the founder of Equi-tox Pharmaceutical Research &
Development, a company that discovers and develops innovative
products to improve animal and human health, directly and
through partnerships. He is a Professor Emeritus of Animal and
Veterinary Sciences at Clemson University. Equi-tox was founded
in 1995 to search for ways to alleviate the pain and suffering
of fescue toxicosis in horses, cattle and other animals grazing
on endophyte-infected fescue. This interview was conducted in
October 2007 at Clemson University. Since this interview, the
company has continued with drug development to include over 150
specialty products and has expanded its customer list to over 5000
veterinary clinics.
— Judith Campbell

Dee Cross

Dee Cross
I am originally from Kentucky and have a Master’s and a
PhD from the University of Kentucky. I became a professor
at Clemson University on January 12, 1973 and taught in the
animal and veterinary sciences department, even though I
am not a veterinarian myself. I retired in 2004, as Clemson
no longer needed my services.
I grew up on a farm in Western Kentucky. My dad was
primarily a root-crop farmer and, as a result, did not take
very good care of our livestock because they did not generate
as much income as his crops. So after a while, taking care of
the animals became my job. As a result, I became interested
in livestock and continued in school studying biological
sciences. I majored in animal science as an undergraduate
and minored in chemistry and biology. Then, I went to the
University of Kentucky and earned my PhD in nutrition and
a minor in biochemistry. After graduating, I decided to come
to Clemson and began teaching PhD students in the animal
physiology program.
However, after a number of years, I started a new focus in
nutritional toxicology. I began this new focus by teaching
pharmacology to PhD students. Many of these students went
into medical fields or became physiologists. I combined my
background in pharmaceuticals and animal science, and the
result was nutritional toxicology.
In 1987, I began to research a problem concerning a toxin
in grass-grazing animals. The most predominant grass in
the United States is a grass called fescue. When you look
around campus, the green grass that you normally see is
fescue, which was released a number of years ago by the
University of Kentucky after originally being imported from
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Europe. I am going to tell you a little story about how we
started with fescue grass and how our work evolved into the
startup company, Equi-Tox, at Clemson University.
For years, we noticed that cattle feeding on fescue were
not performing as they should. In fact, they seemed to be
showing signs of toxicity. A plant pathologist working for
the USDA finally figured out that fescue had an endophytic
fungus. This fungus is quite unique because it grows inside
the grass; while most fungi are external. You usually see
fungi blowing in the air or growing on various things, but
this one was quite deceitful in that it was hiding in plants. So
we combined “endo,”meaning inside, and “phytic,” meaning
plant, and called it an endophytic fungus.
It turned out that this fungus was producing certain toxins,
which were really natural pesticides. Many plants have
protective mechanisms, which is exactly what this fungus is
for the fescue grass. The plant’s development of this fungus
was a protective genetic phenomenon: the endophytic fungus
releases toxins that make the fescue a very hardy type of
grass that is thus able to grow throughout the United States.
The fungus’ toxins are essentially natural pesticides that keep
insects from eating the plants and also make the grass more
drought-resistant. There is a kind of a symbiotic relationship
between the plant (the host) and its endophytic fungus.
However, it was causing problems for livestock.
We began to notice that when the cattle grazed on fescue
grass, their respiration rates were very high, they were not
lactating or milking as well, they had lower weight gain, they
were panting abnormally (especially in the hot summertime),
their body temperatures were higher, and they had problems
with their hooves.
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In very toxic cases, the worst-case scenario would be that
the toxin was so bad that it caused vasoconstriction in the
limbs and crippled the cows. There were even some cases
in which the cows’ feet would come off at the ankles due to
vasoconstriction, and in the winter, poor blood circulation
also caused the tips of some of their ears to fall off. So, this
toxicity was an obvious problem for cattle.
Approximately 100 researchers in the United States (at least)
were working on this problem because it was a significant,
multi-million-dollar issue in terms of livestock production.
Initially, I chose to concentrate on equine toxicosis primarily.
Others observed that horses grazing on fescue showed more
severe toxicity symptoms as compared to other animals.
However, prior to our work, no one had ever run a control
study to document these findings. So, I set up what is called
a two factorial controlled study in which I had horses graze
on the infected fescue—we called it fungus infected—and on
fungus-free fescue.
At that time, plant breeders had bred a type of fescue that
was fungus-free. We thought, “Well, that’s the solution,”
but this grass did not solve the problem because without
the fungus, the plant was not hardy. The grass did not have
that symbiotic relationship or those natural pesticides, so
it did not produce as well. As a result, if we had a hot, dry
summer, we would lose the plant, and if we fertilized it, the
production was low. So, we ultimately had to quit using that
particular type of grass on a large scale.
However, we did use it in our controls and were able to
document the exact effects the toxins had on horses. For
example, the average gestation length before a mare has foal
is about 338 days, or approximately 11 months. However, we
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found that the mares that grazed on the endophyte-infected
fescue had gestation periods of about one year, almost a
whole month longer than normal. You can imagine the
effects of going a month longer in gestation before foaling!
No wonder these horses were having such bad problems.
Also, we found that about half of the mares had stillborns
at foaling because the foals were encased in the placenta.
Some of them suffocated because the placental membrane,
what we call the chorioallantois, was thickened, making it
too difficult for the foals to break through. When a foal
is born, he wants to break his nose through the placental
membrane, take a big breath, and come alive. However,
when he takes that big breath without breaking through the
placenta, he just pulls the chorioallantois up against his nose
and eventually suffocates. You can cut the foals out and save
them if you get there in time, but normally they suffocate
because the mare gives birth when no one is around.
Also, almost all of the mares feeding on the infected fescue
(except for one) were what we call agalactic: they did not
have any milk. On the other hand, all of the mares on the
good fescue (again, except for one) were milking fine. So,
we found that the infested fescue caused a huge problem in
the mares’ lactation. There were also higher rates of what we
call placental retention afterbirth in addition to rebreeding
problems; the mares on the infected fescue could not breed
as well after their initial foaling. Some of the foals whose
mothers were on the infested grass did live, but they were
not has hardy as the other foals, at least not for about three
weeks after birth. Once the mares were off the toxic fescue,
they recovered and did pretty well, though.
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But there was an even bigger problem: the mares feeding
on the toxic fescue had dystocia, or foaling difficulty, and
were not prepared for foaling. Their gluteal muscles did not
relax; their vulvas did not swell; their udders did not develop;
and their cervixes did not relax enough for the foals to pass
through. A good corollary to this situation is trying to pull a
tennis ball through a shotgun; you just cannot do it, and you
are not going to be able to save the foal in such cases. Almost
100% of the foals who birthed in these conditions died.
What we were trying to do at that point was save the mares,
and they were so unprepared for parturition that we lost a
high percentage of them during the birth process as well.
So, as you can tell, the result of the toxic grass had horrible
effects on horses.
I had a graduate student, Jim Strickland, who worked
on this. He was a great student and got his PhD here at
Clemson. Now, he directs a whole team of USDA scientists
at the University of Kentucky doing research with forages
and livestock. When he was working on this study, we
developed a bioassay for these toxins, which we discovered
were ergotalkaloids. This bioassay was very important
because it enabled us to study the toxin’s mechanism of
action. However, developing the bioassay was difficult
because assay techniques at the time were very complicated.
So we developed this bioassay system that enabled us to pull
tissue slices out of the pituitary glands of rat brains and still
keep them alive. After we removed these slices, we perfused
them with toxic alkaloids. The pituitary is located at the back
of the head, close to the brain; part of it consists of neural
tissue with neurotransmitters from the brain controlling its
function. So, developing this bioassay was a very delicate and
complex process.
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Basically, our theory centered on dopamine production,
which affects the anterior pituitary by reducing the release of
a hormone called prolactin. I began studying dopamine in
order to create a theory as to why the infected fescue grass
caused so many problems. On a biochemical level, dopamine
affects the pituitary by inhibiting adenylate cyclase, which
converts ATP to cyclic AMP and is necessary for prolactin
inhibition. Interestingly, what we saw in all of these horses
that were grazing on the infected fescue was prolactin
inhibition, which led to lactation problems.
We started testing that theory, and I thought, “If I can block
that receptor up there where the dopamine activates those
cells, maybe I can reduce the inhibition to allow prolactin
to be produced normally.” I started studying D2 dopamine
receptor blockers for those particular pituitary cells in order
to find a method to block the alkaloids, and we developed
the bioassay system to see if those alkaloids were actually
being blocked. This took us about three years.
I then began screening drugs to reduce the affects of the
alkaloids and the dopamine, and we found a drug called
domperidone did just this. With this drug, we successfully
blocked the dopamine and alkaloids in vitro. We tried other
drugs, of course, but decided to stay with this one because
it did not cross the blood-brain barrier. Drugs that do cross
this barrier, which are often used as psychotropic drugs, had
too many negative side effects and safety issues. Liabilitywise, we could not put a drug like that on the market
because horse owners would have eaten us to the bone by
lawsuits. So, we stuck with domperiodone.
We moved to the field very quickly with this drug. Normally,
when you develop something in the lab it kind of blows
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up when you take it out into the field to test on actual
animals, but that was not the case with domperidone. In
1991, we took it into field testing, and I began feeding the
mares originally on the control pasture the toxic fescue in
combination with oral doses of this new drug. I started them
on this regimen 30 days prior to their expected foaling and
continued until they foaled.
At the level we initially administered the drug, the mares
started looking like they were getting toxic again, so we
doubled the dose we initially gave them. Eventually, when
we adjusted the dosage to 1.1 mg per kg of body weight,
the mares started responding. We were lucky, too, because
the drug worked during the first study it was used, which is
rare. The mares that were not receiving the drug were still
having problems, but we started seeing that the mares on the
drug foaled on time, had healthy foals, and were lactating,
and they did not have those thickened placentas. The drug
eliminated every one of the symptoms related to the toxic
grass because it blocked those receptors.
For about eight years, I did not release the fact that the drug
also had another effect, which we call the alpha-1 receptor
antagonist effect. We kept it quiet because if we released
this information, we knew that the big drug companies
might copy it. So as far as I let on, the drug was just a D2
dopamine receptor antagonist, which was how we initially
classified it. However, the fact that it was also an alpha-1
receptor antagonist became very important in solving this
problem. Actually, it was kind of a miracle—a lot of it was
just very fortunate.
After our success with the horses (about 24 in all), we started
working with beef cattle. To make a long research story

ACORN 47

short, the drug worked great on beef cattle as well. We did
studies on cows, calves, and steers and found that the drug
eliminated the toxic effects of the infected fescue grass in all
of them.
The next problem we faced was with the Food and Drug
Administration. It cost us about $6,000,000 to clear the
drug for horses; however, for cattle, it would have been about
$40,000,000 to develop all of the data the FDA wanted for
cattle, and that was if we did not run into any problems.
Only a big company could have afforded that. The reason for
this large expense is that the FDA has to be sure that none
of the drug residue will harm humans if they consume meat
from cows on the drug. This was not an issue for the horses,
though, because they are non-food animals in the United
States.
In 1991, we felt like we had a strong enough solution to the
fescue toxicosis problem, so we disclosed our findings to
the patent committee at Clemson University. The patent
process takes some time, so the patent for domperidone was
not issued until 1994. The patent covered domperidone
use for all mammals, not just for horses, and even included
humans. Some parts of the patent also included the use of
ergoalkaloids as well.
In 1994 and 1995, I tried to sell the patent to a few big
companies that had the wherewithal, knowledge, and money
to clear the drug. Even though a few companies showed
some initial interest in the drug, no one ever really bit into
it, so I was really discouraged. I felt like I had something,
so I came back to the university after all that and said that
I wanted to buy my patent back. In other words, I wanted
a contract that said that I had the right to market my
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technology. The university did not make it easy, but they
eventually granted me the right to have my patent and told
me that I could spend that $6,000,000 to develop the drug.
As I tell people, I knew then that I was like a termite eating
a cross tie, but I did not realize that the cross tie was filled
with creosote.
I signed an agreement with the university to develop the
technology and established a startup company, Equi-Tox.
We also hired a consulting firm in Dallas, Texas that had
people who knew how to clear drugs. The whole process
is extremely complex; a person can spend a lot of time
and money and still have his study rejected—I am personal
proof of that. Two of my studies were rejected, but we
eventually went to the Center for Applied Technology at
Clemson University (they call it the CAT Center) and started
developing the drug.
The process to get a drug accepted by the FDA is
multifaceted. We had to prove the safety and efficacy of the
drug and go through what they call “good manufacturing
practices,” or GMP, for short. By far our biggest challenge
was finding the funds to keep the process rolling. Even
though it was kind of tough, the research was great: we
worked hard; it was fun; and we were doing something no
one had ever done before, but clearing it through Food and
Drug was a challenge! That was when we only slept two or
three hours a night trying to figure out how we were going to
generate all of the funds to keep the process moving along.
As we were in the clinical efficacy stage of this process and
were trying to get approval for the drug under clinical testing
out in the field, we got a call from a large horse farm close
to Washington D.C. Apparently, they learned about our
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research because I had given some presentations about our
work. They said that they had exactly the problem that I
described and that they were losing mares and foals after
having paid hundreds of thousands of dollars for breeding
fees. It was a financial disaster for them as a thoroughbred
farm.
I told them that we could not ship the drug because we were
restricted, and they responded by saying “Well, let us see
if we can do something about that.” I guess they knew the
right people, being located near Washington, D.C. because
not long after that, I received a call from the FDA saying that
I could go ahead and ship the drug to some of those horse
farms because there was no alternative therapy. So, through
this unique process, we were able to start shipping our drug
and generating a little income to keep the research going,
which was all under FDA regulations.
In 1999, we completed a new facility for Equi-Tox because
the CAT Center was not up to GMP standards; it did not
meet all of the requirements that the FDA wanted for a drug
manufacturer, so we had to build our own facility. It is an
office complex with a manufacturing facility in the rear, and
we built it like a horse barn to reflect our products.
I now have nine patents. We developed various aspects of
the drug in the States and in other countries. In December
1998, the initial patent for the drug was approved. Then we
started noticing that most mares, whether they were on the
infected fescue or not, began rebreeding better after being on
the drug. We did some control work and eventually patented
a method for promoting ovulation, parturition, and lactation
in mammals.
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We also got patents that approved the drug for laminitis,
which improves blood flow to the foot (which is important
for horses) and for ease of parturition in pregnant mammals.
We hope that someday women will also be able to take
this drug to ease the labor process because it seems to
make laboring and breastfeeding much easier. Anyway, I
hope to develop this drug further in areas related to easing
parturition.
We also received international patent protection and cleared
the drug in Australia for follicular growth, which is related to
ovulation and reproduction. We are currently in the process
of clearing it in New Zealand, Canada, and then several
places in Europe as well.
So in summary, we had to form a lot of partnerships and
a lot of contracts with different companies. In 2000, we
signed a marketing agreement with the Bayer Corporation,
a German-owned company who was very interested the
drug. However, things did not work out with them, and
we eventually dropped the contract. Currently, we have a
contract with a company in India called Reddy-Cheminor
to synthesize our drugs. Of course, the work they do has to
be done under GMP synthesis, so they filed the GMP under
what we call the drug master file, which was approved.
We also hired a lab in Indiana, a human pharmaceutical
company, to complete all of the GMP requirements in
the United States, and we now have a new contract with
a company out of the United Kingdom called Dechra.
They are the largest veterinary pharmaceutical company in
theUnited Kingdom, and they wanted to develop new drugs
in the United States. So, they bought our technology, nine
patents, and all of the FDA material that I developed over
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the years. Essentially, I sold this drug to another company;
I received some upfront payments, and I will get royalties. It
should be marketed under their brand name next fall.
Interviewer
Has Equi-Tox been completely self-funded?
Dee Cross
Now which comes first, the egg or the chicken? If I knew
what I know now, I would have taken investor capital and
cleared the drug quickly because we had a lot of people who
wanted to buy stock in the company, but at that time, we
elected not to. So, Equi-Tox is wholly owned by me and my
wife; we financed it and have never sold any stock.
Luckily, I have rental property and own a little bit of land,
so I was able to borrow money against my equity to start the
company. Then we got a break with the FDA because of the
demands from the horse farms and their desire to use the
drug. This demand enabled us to develop the drug under an
investigational number and ship it out to these horse farms,
which gave us the funds to keep the research running on
track. Now, we are a debt-free company that nobody owns,
even though Dechra now owns our technology on this one
drug.
However, we have developed 150 other programs for
specialty products, and we have accounts with 5,000 equine
clinics in the United States. I had to be able to create
a profit in order to keep the company going, so I had to
become profit-minded, but the best part of this whole process
was that we solved a major problem in the animal industry.
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We also had the opportunity to educate many students who
were then able to get good jobs because they were associated
with this research. Another really great benefit to this work
is that every large animal veterinary clinic in the United
States now knows where Clemson is. Even though we do not
have a vet school here, every veterinary pharmacology book
published recently has our research about fescue toxicosis in
horses, domperidone, the dosage, the effects, and so on. So,
our work was about solving problems and about creating a
good reputation for the university.
In order to create this company, I really had to learn how
to build in the business world. Believe me, when you walk
into a large company and say that you are a professor, those
entrepreneurs will pick your bones. Luckily, we did not sign
any contracts early on. Generally, the big companies will start
out a deal with a sucker contract just to see how vulnerable a
person is. I hate dealing with contracts, but it is a necessity;
you just have to learn how to play the game.
Interviewer
You mentioned that when you had the technology you first
went to a larger company, and they turned you down. What
is your speculation as to why they did not go with this drug?
Dee Cross
I pushed it a little bit for cattle initially with Elanco, but they
were not interested in horses. The reason for this had to do
with a lawsuit against them relating to a drug they developed
for cattle; some horses ingested it unintentionally and died,
so they just did not want to deal with horses.
As for the other large companies, I think they screwed up.
I just do not think they knew what I knew. It was hard for
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me to convince them to pursue this technology because, to
them, I was just a professor from Clemson University, which
is not even a veterinary school, and I wanted them to invest
in this drug for a problem that they knew little about, and
they were not well versed in the technology at that point, so I
could not convince them.
Interviewer
What does lack of support mean? You don’t have to name
names, but just say what does the lack of support mean? How
would that come about?
Dee Cross
Probably one of the most motivational forces in society is
jealousy. You get somebody jealous of you, and you have a
problem. Now that I am retired, I can talk about this. When
you are outdoing some of your peers who think of themselves
as super-scientists, sometimes you create some friction, and
then you start seeing little roadblocks being thrown out
there. I had to learn how to deal with that; I had to be
tough and smart.
Interviewer
What about your role as an academic? It might appear
that you were focusing on commercializing a technology
rather than on publishing in academic journals. Was this a
problem for other faculty in your department?
Dee Cross
Yes, that is the big argument. Fortunately, I was able to
publish as we went along and still protect the patents because
I did a lot of the patent work later, away from the university,
even though we ran it through the university patenting
office. That is a potential problem, though.
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First of all, look at the students who came through this
program; they are very successful; they got good jobs; they
learned a lot; and their data was published. So it is a pretty
hard argument, but in some cases it is valid I guess. There
is a proper balance; you cannot go in just one direction. The
university is a complete system with all facets, and the higherups want faculty to develop technology. If the university had
not offered me the opportunity to develop the technology, I
probably would have just piddled along and never done this.
That being said, I figured that if I patented, I would get some
kind of reward out of it. Then later, when no one would
buy the drug, I figured I would try to gain these rewards by
negotiating a contract with the university because I knew I
had something. Now, the atmosphere is better because we
have a research foundation and ways to protect those people
who have technology that needs to be developed.
So had that other argument won, you know what would be
the result? There would still be a huge problem in the horse
industry; we would still have mares and foals in pain and
suffering. It was an economic solution as well. One farm
told me that on one foal, we saved them about $1,500,000 by
treating one mare, and it cost them just $75.00 for the drug.
There are a lot of people I need to thank for helping
me through all of these little roadblocks. The Clemson
University administration who supported me; the Director
of the South Carolina Experiment Station; the then-Director
of Technology Transfer, Bob Gillan; Ed Page, who is now
retired; Steve Chapman, the University Attorney with
Patents and Technology; and Vincie Albritton, who is now in
charge of Technology Transfer.
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If it had not been for these people, I would have quit,
but they kept saying “Keep going. Keep going. We are
supporting you.” Because I had some support up at the
higher levels, I felt like I was okay.
Now, we are treating all kinds of animals. As one
veterinarian said, “This drug will put an udder on an anvil,”
so we can help a lot of animals with it. We are treating
dolphins, camels, alpaca, elephants, rhinos, apes, sheep,
goats, and a number of other species. Now, we are even
developing several products for dogs. Even though we are
going to give up our main drug, we plan to develop other
things at Equi-Tox, and dogs are one of our biggest targets.
Interviewer
Are there any adverse side effects of the drug that you know
of?
Dee Cross
Not that we know of. We are actually repeating the
safety study right now. It is the hardest study I have ever
done in my life. I had to repeat it because the first study
did not meet all of the GLP, or the “good laboratory
practice,” requirements. So, we are repeating it with some
veterinarians in Tennessee. The first study was good; I just
did not have all of the knowledge that I do now, so I did not
get all of the checkboxes right at first.
However, on our label it will say that the drug can cause
premature lactation. If a mare is not ingesting much infected
fescue and she overloads with the drug, she may start leaking
milk. However, that actually turned out to be an advantage
for us. Currently, about 25-30% of our business is from nonfescue mares that are not lactating well. If an owner knows
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that his mare is not going to lactate, he can start her on the
drug before parturition, and she will be flowing milk by the
time she foals (if she is capable of lactating in the first place).
Some farms start mares on the drug right after foaling if they
see that the horses are not lactating well.
The label will also say “Do not administer to a horse that
has an intestinal blockage due to colic” because the drug
stimulates the gut. If there is a certain kind of blockage in a
horse’s gut, the drug can increase the pain level. So those are
the two safety issues.
I should mention that for safety’s sake, every drug we make is
administered as a prescription through veterinarians. We do
not ship to veterinarians’ clients unless they ask us to.
Interviwer
How do you administer the drug to horses?
Dee Cross
We started out with a molasses carrier for the drug; it worked
great, and the horses loved it, but the FDA said it looked
like we may be getting a little settling of the drug. We did
not think this mattered because we gave the horses an entire
oral dose, so they were getting the proper amount of the
drug regardless of any settling. But, the FDA argued that
the molasses may not be the same volume if it is 100 degrees
versus 20 below or something like that, so we had to repeat
the GMP process.
I ended up putting the drug in a carbopol parabens polymer
and made a gel to suspend it. Now we have a five-dose
syringe with a dial-a-dose mechanism: just turn the dial,
the the drug comes out, and there are four doses left. Then
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we had to prove through GMP that there were no safety or
accuracy issues with the syringe.
We also had to do stability studies on the drug, which took
two years. We had to assay all of the other components in
the syringe as well, like the parabens, the methylparabens,
the apple flavor, and everything else we put in the mixture.
Then we had to do batching. We started with 10% batches
and proved that everything was okay with them. Then, we
had to scale up the batches to manufacturing levels.
Then, the facility had to meet all kinds of cleanliness
requirements: the floors, drains, air, water, etc. We had to
test our water and run bacterial analysis on it, and then we
had to do the same thing for our syringes, and on and on.
Inspectors can always find something to shut a plant down.
The FDA is not rational. For example, our drug was used on
non-food animals, and it showed no safety problems. Before
it was cleared, we treated 100,000 mares with no negative
results. The FDA told me once, “We know the drug is safe.
You would have been sued and put out of business if it was
not safe,” but they still put us through the same requirements
as those for a human drug except for tissue analysis. That is
why the whole drug-making process costs so much and takes
so long.
Interviewer
I was just wondering if there a chance that this drug will be
marketed to women?
Dee Cross
Yes, actually there is. Our daughter-in-law had her baby at
the hospital in Charleston. While we were visiting, I asked
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them if they had ever heard of domperidone, and they told
me that they were actually using it now.
But here is the bottom line: big pharmaceutical companies
and the FDA work together. They do not like it when little
companies come along because we are not familiar with the
drug-manufacturing process, which costs them a lot of time.
Big pharmaceutical companies make the process go much
faster, which justifies their positions.
Interviewer
How were the doctors getting the drug?
Dee Cross
They were not getting it from us. We stayed away from
humans for liability reasons, but they read our research and
began getting the drug through formularies. A formulary
is a very important part of the pharmaceutical industry.
The FDA hates them, and big pharmaceutical companies
hate them, but when you have a unique problem, you need
a special formulation to solve that problem. A doctor can
prescribe a pharmacist to make him that formulation for his
patients, and that was how domperidone was being used.
Interviewer
Did companies look at the patent to see what the
formulation was?
Dee Cross
We have had so many violations of our patents, and I have
hired patent attorneys and sent letters. We would send the
formulary makers threatening letters saying that we were
going to sue them, but then I began to look at it from a
different standpoint: we would have needed about $100,000
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to file a patent lawsuit, and if the company we were suing
was bigger than us, they could have outlasted us and busted
our patents. We have wholesale black marketing of the drug
going on, but I have turned that over to Dechra now. But
they say that it is a sign that you have a good drug when all
the thieves come out and start selling it.
Interviewer
What kind of patent do you have?
Dee Cross
We have a use patent, not a formula patent, so we could
not protect against the formulary development. However,
I patented the drug in terms of all of the methods for
administering it, and I have nine patents covering everything
I could think of in terms of the drug’s use. It is a matter of
getting in the court with lawyers and everything, and at my
age, I have decided that I am going to take a buyout and let
the big pharmaceutical company deal with this problem. So
that is what Dechra is doing now; we transferred all of our
files on patent litigation to them. That is what happens with
patents; unfortunately, you have to be big enough to defend
them.
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Michael Bolick
Selah Technologies

Michael Bolick is the founder and CEO of Selah Technologies,
which is based in Pendleton, SC. Selah Technologies is an
advanced materials company focused on the development of
nanotechnology-enabled products for the biomedical and consumer
electronics industries. Michael founded Selah Technologies in
May 2006. He has more than 17 years of experience in designing,
starting, building, managing, and growing advanced materials
manufacturing companies. Before starting Selah Technologies,
Michael spent ten years in the pharmaceutical industry as
an executive with a Greenville-based contract research and
manufacturing company. This interview was conducted in July
2007 at the Clemson University Renaissance Center. Since this
interview occurred, the company has hired eight full-time employees
and has raised over $1.5 million through a private equity
placement.
— Elena Shorb

Michael Bolick

Interviewer
So the question I would like to begin with is how did you
develop Selah Technologies? How did it happen? You can
start anywhere you want.
Michael Bolick
In my youth I was awarded a scholarship to attend a Hugh
O’Brien youth leadership conference. The conference
celebrated our nation’s free enterprise system. My interest
in running my own business took root in this setting. After
earning a degree in Chemical Engineering from North
Carolina State University, I accepted a job offer to work
on a startup team for a Japanese-owned specialty chemical
manufacturing plant in Chattanooga, Tennessee. I really
enjoyed the experience of helping to design the facility,
specifying and purchasing equipment, tracking construction
and equipment installation, writing operating procedures,
hiring and training people, etc.
In 1997, I was blessed with an opportunity to move
to Greenville to help start up a Swiss-owned active
pharmaceutical ingredient (API) manufacturing plant. At
that job, I held more responsibility, but the process was
basically the same: a grassroots startup of an advanced
materials manufacturing plant. Once again, I thrived in the
startup setting.
Over those past 15 years, I enjoyed a successful and
satisfying career. But about two years ago, I realized that
I could no longer accept the thought of continuing in the
same direction. I considered looking for another startup
opportunity, but this would most likely require relocation,
which was not an attractive option. I have three children,
Perry (14), Connor (12), and Madison (9), who have grown
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up in the home we built here in Greenville. The last thing I
wanted to do was move again for a new opportunity.
Coupled with this was the realization that I really wanted
to finally reach for my dream of building my own company.
My wife Sheelah was very supportive during this process.
We talked and prayed together and decided to start a new
business.
Once we had a plan in place, I reached out to a group of
more experienced business people in the area. I was very
fortunate to have a group of people who were willing to
block out some time and listen to me. When we sat down,
I laid out the situation and asked for input. My side of
the conversation usually went something like this: “I am
planning to make a transition to start my own business. I
need to make a break. I need to make a change, but I do
not want to do it in a rush. I want to do it in an organized
manner. Do you have any suggestions of how best to
proceed?” I got a lot of really good advice and thought
starters from this set of meetings.
I looked at a number of options. I looked at buying
franchises or existing businesses. I have friends who
made the transition from corporate life to entrepreneurial
ventures. One started a bread-baking business. Another
started an attractive high-end butcher shop. I seriously
considered that route, but I kept coming back to my desire to
start something that would allow me to leverage my advanced
materials manufacturing background.
At about this time, I heard about the InnoVenture
conference here in the Upstate. The idea behind the
conference, as I understood it, was to mix inventors,
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entrepreneurs, and investors together for collaboration and
idea sharing. I took two days of vacation and attended
InnoVenture 2006, consciously looking for an opportunity
with my mind wide open. Several people were praying for
me to find what I was looking for, as my search had not
yet borne fruit. I joined them in asking for guidance and
wisdom. Most of my prayers were along the lines of “If there
is something here, please help me to hear it; help me to
recognize it.” And I will tell you there was a really exciting
vibrancy to the community that was there. There were a lot
of opportunities to consider. Unfortunately, to my chagrin,
still nothing clicked for me.
That is, until I saw the presentation by CURF (Clemson
University Research Foundation) representative Matt
Gevaert. Matt presented on a technology that had been
invented in Clemson’s advanced materials laboratories.
The technology was called “carbon dots,” short for carbonbased quantum dots. Quantum dots are light emitting
nanoparticles that are very promising for a broad array
of applications, including cancer detection and other life
science applications. The main point I remember hearing
was that this new technology was based on carbon rather
than on cadmium or other heavy metals. A carbon-based
quantum dot was expected to be less toxic than heavy metals
and would, therefore, have a compelling advantage in the
marketplace. The market was growing rapidly even without a
heavy metal quantum dot alternative. This really caught my
attention.
I remember it was not a very long presentation. Afterwards,
I went out to the CURF booth and spoke with Matt Gevaert
and Vincie Albritton. I handed Matt my transition card with
my personal contact information and said, “I want to start
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my own business, and this technology looks very attractive
to me.” About three weeks later, I signed a NDA—NonDisclosure Agreement—and got a chance to really dig into
the technology.
As I said earlier, for the last ten years I have worked as an
executive for a contract research and manufacturing firm
servicing the pharmaceutical industry. Sometimes we would
make APIs for a drug that was already on the market. More
frequently we produced materials that supported clinical
trials. This means that we made small amounts initially and
then scaled up production volumes as a given API was taken
to larger and larger clinical trials. Our home run was to
make an API for a company from the clinical trials through
launch and into the market. This experience provided me
with the ability to look at this new technology and see that it
could be very scalable.
Near the middle of May 2006, I formed a company called
Selah Technologies, LLC (www.SelahTechnologies.com).
The name “Selah” means “to pause and reflect on what has
been said.” Selah Technologies obtained an exclusive option
to negotiate for the technology. Now, this option is not the
actual license; instead, it is a period of exclusivity to conduct
due diligence to determine the value for the base technology
and to develop a commercialization plan. This period is
effectively the start of the business planning process.
Around this time, there was a paper that was published
in the Journal of the American Chemical Society (JACS).
The paper described the implications of a carbon-based
quantum dot and referred inquiries back to Clemson. Quite
a few people read this paper and contacted Clemson and
the inventor. Many of these contacts were referred on to
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me. Some of the inquirers came through, and I took the
opportunity to sit down with them and try to evaluate how
we could collaborate to commercialize this technology.
So, as the summer progressed, I realized that we had an
outstanding opportunity on our hands. I entered into
negotiations with Clemson to obtain the license not only
for the carbon-based quantum dots but also for another
technology that allows enrichment of carbon single-walled
nanotubes. Both of these advanced materials technologies
are referred to as “platform technologies.”
A platform technology has great potential in a number
of vertical markets. To be able to license two platform
technologies is a blessing. It means that we have more than
one arrow in our quiver. On the other hand, an abundance
of market opportunities can be a siren song that keeps the
entrepreneur from focusing on a particular “go-to-market”
strategy. This lack of focus is sometimes referred to as trying
to “boil the ocean.”
In September, we concluded negotiations, and Selah
obtained a worldwide exclusive license to develop and
commercialize both carbon-based nanotechnologies.
I have to tell you that Clemson was very supportive, and
they were great partners in the negotiation. CURF was a
good steward of the technologies invented at Clemson. The
CURF representatives really pushed me to demonstrate that
I had the ability and a sound plan to move into the market. I
also think Clemson and CURF were interested in engaging
with the entrepreneurs in South Carolina to help transition
our state to a “knowledge-based” economy.
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Once Selah had the exclusive license on both technologies,
I was able to kick into full gear. I took advantage of the
preliminary contacts that we put in place to start what we
considered to be our strategic intent. This intent was to
build relationships with major multinationals that already
had ongoing nanotechnology research programs.
We are bootstrapping the business right now: building value
in the business before we seek outside investment. This is
a challenge to balance properly. I see myself as a steward of
this opportunity set.
So, in a nutshell, that is the story behind how Selah was
developed. We were blessed to have a number of potential
industrial partners, and customers responded very early and
very positively to Selah’s technologies. I cannot get into
the specifics just yet, but these interactions have been very
encouraging.
I will conclude by mentioning that in January, our Chief
Technology Officer, Dr. Andrew Metters, joined us from
Clemson University. Before joining our team he was an
assistant professor at Clemson. It was decided that before he
joined the project full time, he would finish out a previous
commitment to his students. He had two students who had
not yet defended, so he worked on a part-time basis for Selah
until just recently.
And then, in March of this year, Ken Morgan, our Chief
Operating Officer, joined us as well. So we have the
technology in place; we have potential partners and
customers encouraging our growth; and now we have a core
team of motivated folks that are all pulling together. Selah is
blessed with a lot of momentum.
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Interviewer
So, let’s start at the beginning in terms of your background
knowledge. It sounds like the expertise that you brought
to the project was primarily about understanding how to
upscale manufacturing.
Michael Bolick
That is correct.
Interviewer
What about your background in marketing?
Michael Bolick
Marketing and finance are two areas that are the least
familiar to me. In my career, I learned that everyone
involved in a startup has to wear a lot of hats. I also learned
the lesson of trying to take on too much by myself. Finally,
I learned to delegate responsibilities, to empower others, and
to share the load.
I spent my entire career serving customers in the advanced
materials manufacturing business. I know what it means to
work with customers: day in and day out for both long-term
and short-term projects. Making sure that you communicate
effectively is the key to doing business.
You learn how to discover and be sensitive to what your
customer’s real needs are, and you communicate with them
to ensure they are always fully informed. It is important to
establish a relationship based on trust and ethical dealings.
So in summary, I have a solid set of skills that will be directly
translatable. There are also some areas where for which I do
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not have experience, but I am gathering an extended team of
associates and advisors that will fill in the blanks.
I believe that without counsel, plans fail, but with many
advisers, they succeed. That is not my concept; it is from the
Bible (Proverbs 15:22). As you broaden the group of people
who give you advice and counsel within a certain context,
you awill make your decision making more effective.
Interviewer
Could you elaborate on some of the kinds of advice you have
been given to help make the business become a reality?
Michael Bolick
Well, I have to admit that a few of my friends thought I
was going down the wrong road. They would say “You are
making great money. You have an excellent job. How can
you walk away from such a successful career? What are you
thinking?”—that type of thing.
I listened to the whole range of perspectives, but I knew
it was time to make a change. I believe that if you are not
careful, it is very easy to float along in the security of a larger
company. Do not get me wrong, corporate politics and
layoffs are not much fun, but there is a set of rules by which
most corporations and people play. Lifetime employment
does not really exist anymore from my perspective. Typically,
you are going to have to keep going and build a career with a
series of companies.
In this setting, however, you do not have the opportunity to
influence the direction of the company as readily as you do if
you start something with a team of people and you are right
there at the center of it.
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In any event, there were a few people that really made a
difference in my decision. One really good friend, who has
his own business here in town, encouraged me to seize the
opportunity to realize my dreams. He said, “Look. I know
you. If there is anyone I know who should run his own
business, it is you.”
I said, “Well, you know...”
He said, “No, you are not hearing me. You need to start your
own business.”
Once I psychologically made the leap and said “Okay, I can
accept the fact that I am taking a huge risk and that it may
not work out,” I realized that I was in it for the long haul.
I have great faith in God’s providence, and this gave me
courage. At the end of the day, I knew that I had no idea
whether or not Selah Technologies would turn out to be a
success, but I was convinced that I needed to make a go of it.
At this point, I realized that I needed to broaden my advisor
base. I started looking for serial entrepreneurs in the local
community who would be willing to guide me. I was blessed
to find several people, who were willing to stop, listen, and
give me counsel. Most of these individuals did not have
advanced materials manufacturing experience, but each had
entrepreneurial start-up experience, including successful
exits.
I said, “Okay, what do you think of this idea?” I laid out the
basic technology information and the market analysis that I
had compiled. I picked their brains. I asked “How would you
approach this? What do you think I should do?” I spent a
couple of months bouncing ideas off people.
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And the responses I got were along the lines of “You need
to read this book; you need to look at this opportunity; etc.”
I was introduced to the concept of how a lifestyle business
compares to a growth-mode business. Other issues were
pushed to the front burner: “What kind of financing do I
need to have? Where am I now in the process? What do I
want the company to be when it grows up?”
I had several mentors reinforce the idea that with a
technology-based business, you have to push to get your
product to market in a focused manner with an eye on the
next big thing coming along behind you.
I was fortunate to have many introductions from
InnoVenture 2006. I also reached out to the Greenville
Chamber of Commerce. I was introduced to and joined a
group called NEXT at the Chamber of Commerce, which
focuses on creating new entrepreneurial infrastructure in the
Greenville area. I engaged with a number of entrepreneurial
support organizations available in the area.
Interviewer
At what point had you written a business plan?
Michael Bolick
I had an early draft, but it needed improvement. I was
fortunate to learn this before I needed to raise money. You
do not want to go to Angel or institutional investors unless
you are well prepared. You only have one chance to make a
first impression. People will establish perceptions about your
competence based on your initial pitch.
On the other hand, I was also aware of the danger of getting
so preoccupied with establishing an infinitely detailed plan
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that you forget the reality that things will vary from your
plan. You have to be able to adapt. Practically speaking,
making projections longer than three years is extremely
difficult. Then there is the balance between projecting the
exciting future you see and establishing realistic expectations
for a number of stakeholders.
I finally settled on a business plan that is tied to critical goal
categories that then flow out to action items for our team.
We plan to keep an eye on the plan and to adapt and update
it as needed to take advantage of changing market conditions
and opportunities.
Interviewer
So at this point, are you self funded?
Michael Bolick
Yes. My wife is my partner. When we started the business,
we reviewed the opportunity and our financial situation.
Then we decided on an amount of money we thought we
could afford to invest. At that time, we set out milestones to
gauge our progress.
Looking back, we are pretty close to that original set of
expectations, but I have to admit that in the planning, I did
not include all of the other expenses that I had historically
paid for with my prior paycheck. I knew these expenses were
still going to be there, but I think I just blinded myself to the
problem.
Every successful business person I know tells me that “cash
is king.” I am reminded that if you are not extremely careful
and you do not plan in a safety factor beyond what you think
is likely to happen, you will end up running out of runway
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before you can take off. Fortunately, because my wife is an
excellent partner and my best friend, we have been able to
get through these types of things and not “sell out early” to
the detriment of our family or the company.
Our goal is to build an advanced materials manufacturing
business selling to the global marketplace from the Upstate
of South Carolina. I see this as an opportunity to step in
and engage as part of our state’s transition to a knowledgebased economy. We are fortunate to be in the right place at
the right time to do good, solid, ethical work during a rising
tide of opportunity. We are so blessed to be here. This is
a wonderful community. The people here are very friendly.
There are a lot of people moving in from other parts of the
country because they want to be part of this great thing we
have going on and where our state and our region is going.
Some people have said that the transition to a knowledgebased economy is the end of manufacturing in South
Carolina. I respectfully disagree. Our community knows
how to do manufacturing. On the contrary, the transition to
a knowledge-based economy is a means provided to enable us
to save and grow manufacturing in South Carolina.
Interviewer
How did you do your due diligence when you had the option
to explore the nanocarbon technology?
Michael Bolick
That is probably the most challenging part of this whole
process because of the concept of technology transfer. I
have lead teams doing technology transfer from a number of
customers to our laboratories for more than a decade in the
pharmaceutical industry. Every time you transfer something,
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there are going to be problems. Every time you scale up,
there are problems.
The question is how many problems will there be? Hopefully,
if you have been down a given path a few times, you have
the luxury of experience. Recalling problems similar to
mistakes that were already made, you try not to make the
same mistakes again. Regardless of past experience, when
you have chemistry involved and you try to scale up, you will
likely encounter things that could not be anticipated.
So we are looking at technology that has been proven on a
research scale— in a very small vial, so to speak—in a research
laboratory. We now need to extrapolate the process to a
manufacturing plant. I would have been fooling myself to
think that I could look at that and see every challenge that
we might encounter. But what I was able to see, what I saw
right off, was that there was not some multi-million dollar
piece of capital equipment that would be necessary to begin
production.
I looked at the complicated, expensive, and inconsistent way
that the current market leaders are making heavy-metal-based
quantum dots and compared this to what had been invented
in the Clemson research laboratory. Our process is robust
and highly scalable. It is a very elegant answer to a not so
elegant problem.
At the core of our product, no pun intended, we have carbon
instead of cadmium. I mean we are made from carbon.
Organic life forms are made from carbon. I drink water
every day from a carbon-based water filter.
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I want to point out that we will not just assume that there are
no negative health effects from a carbon nanoparticle, but
I am confident from looking at it initially that the potential
problem is greater with cadmium than with carbon.
So, I am trying to follow up on all of these things. My initial
thought was that this looked like a no-brainer for a base
technology, possibly not for every application, but there are
going to be places where the carbon dot will be a very wellreceived alternative to the heavy-metal-based quantum dot.
I interacted with the researcher at Clemson University,
a brilliant man. I received assurances from him that he
would be a partner with us to transfer the technology out of
his laboratory into our laboratory. Those assurances were
fundamental to my decision-making process. I was brought
up to believe your word is your bond. To have this fellow
indicate a willingness to step up and help was very, very
important in my decision-making process.
Now, at some point you have to stand on your own two
feet, which is why I looked for someone who had Dr.
Metters’ qualifications—not only the qualifications from an
academic perspective and a technical perspective but from a
personality standpoint. I needed to grow the manufacturing
capacity and scale up the process. We do not need to come
up with a different type of dot; I just need to make this dot
be as good as it can be.
Although that happened after we had the license, it is
still part of the due diligence process because I am still
funneling money into the business. I learn more on a weekly
basis about the technologies’ potentials, and fortunately, I
continue to become more confident and thankful rather
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than more concerned. I feel more and more excited rather
than more scared.
Interviewer
Please talk about the specific potential applications of this
technology.
Michael Bolick
Well, I have to be careful with this. The nanotechnology
field is experiencing an intellectual property (IP)
blizzard right now, so I have to be wise about what I
publically disclose. Several years ago, there was a bit of a
nanotechnology patent gold rush. Patent applications were
filed claiming very fundamental things. In some cases,
patents were issued that had overlapping claims, and some
patents had been issued that confused the playing field.
Some of that is getting shaken out now, but when we talk
about taking carbon dots into a particular application,
you have to know that each one of those ideas represents a
potentially different intellectual property position. Each case
might need to be protected by a patent application before
being publicly disclosed.
What we are trying to do now is share ideas about the
potential of our technology without giving away the farm. My
younger son, Connor, gave me an idea for one of the ideas
that we are sharing openly: carbon-dot-enhanced paints. The
idea is to make a paint that glows when you turn on a black
light in a dark room. Imagine painting the walls of a play
room or media room and turning on a black light. The walls
will glow with a fantastic electric blue.
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There is no paint on the planet right now that will do that!
This has never been considered by any kind of quantumdot manufacturer because no one would want to pay for
cadmium-based quantum-dot paint, not to mention the
environmental issues with the disposal of a cadmium-based
product.
Well, one readily available excitation source for carbon dots
is the black light. The excitation source provides the electric
blue wall color. We could also change the wavelength of the
excitation source to, in turn, change the color of the wall.
What color do you feel like today?
This phenomenon is called photoluminescence. Carbon dot
electro-luminescence is another exciting option we want to
investigate. Scientists have already proven that heavy-metalbased quantum dots will emit light when exposed to an
electrical field. With this technology, you would no longer
need the black light; your whole wall would become the light
source.
One of the most exciting areas to employ carbon dots is in
the life sciences. The ultimate goal is to use carbon dots as a
biological imaging agent. In other words, we want to develop
a way to use the dots to find biological targets like cancer
cells as part of a diagnostic toolset.
The first application we are targeting in this area is called
in vitro diagnostics. In vitro means the test is being
performed outside the living organism. A physician takes
a sample of interest (such as a biopsied tissue) and places it
in a Petri-dish-type container. The physician then applies
the carbon dots as part of a testing process to determine if
the sample has cancer cells or some other target of interest.

78 SELAH

Organic dyes are being used in this market, but these have a
number of limitations, including a tendency to photobleach.
Photobleaching occurs when the dye stops emitting light
after only a very short testing period. Carbon dots are much
more resistant to photobleaching compared to organic dyes.
The other example I have described in a public setting
involves skin cancer. I recently had a small growth cut from
the back of my leg. The doctor told me she wanted to cut
away only the suspect cells, but it was a bit of a guessing
game. She said, “There is a balance between cutting too
much healthy tissue away versus leaving bad cells behind.
I am going to send this part off to have it tested.” I had
to wait a few weeks before I found out that the test was
inconclusive and that I had to have more tissue biopsied to
repeat the test. Just imagine how many times per day this
happens. Fortunately I was only dealing with what turned
out to be a benign growth on the surface of my skin.
We are planning to create “point-of-care carbon-dot-based test
kits” that will allow a doctor to spray a carbon dot solution
across questionable tissue. The doctor would then turn on
a special light in the office to light up all of the bad cells. If
there were cancerous cells present, the doctor would be able
to see them with the naked eye. So, when the doctor comes
in to cut out the bad tissue, the margin will be well defined.
If a doctor does not have to guess at the location of the
margin, treatment will become significantly safer and more
effective.
Now, whether the cancer is in a Petri dish or on the surface
of the skin, medical decisions are being made. This means
that any product involved in making a medical decision will
undergo scrutiny by the FDA. The FDA helps to ensure
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that such a tool is safe, effective, and consistent. This is why
we are focused on generating data for in vitro diagnostics
to support an eventual move to in vivo diagnostics: in vivo
means “in the body.”
Looking out to the most exciting in vivo applications, we
wanted to enable doctors to use carbon-based quantum dots
as the imaging agent in full body scans, such as the MRI or
CT scans of today.
We have been blessed with a great deal of potential and
momentum. I see my primary role as that of a steward of
this set of opportunities. We have to watch the cash burn
rate. We have to hire the right team. We must work to get
the business on its feet and then identify and work with the
right partners and collaborators.
Interviewer
Were there problems that you thought would occur that did
not occur?
Michael Bolick
Well, let me think a bit about that one. I envisioned a whole
range of problems potentially occurring. We could have
gone out of business. We could have run out of money
already. Thankfully, none of those things happened.
We could have found it difficult to find outstanding people
to grow our team. Instead, we have been blessed to have
outstanding people interested in joining our team. People
are now coming to us saying “we heard about this great
opportunity. We want to be part of it.” It is interesting to
see that dynamic change.
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I try not to worry. I try to plan for risks and then put things
in place to mitigate those risks. I work very hard, and then I
pray for wisdom and positive results.
Interviewer
Were there problems that you did not think would be
problems but turned out to be?
Michael Bolick
Yes. The actual technology transfer into our laboratory did
not go as smoothly as I had hoped. We have thankfully
moved past this problem, but this delay was more than I had
hoped for. You know, the plain truth is that God does not
promise us a guarantee of an easy road to success on this
Earth. We are sometimes given adversity to strengthen us.
During these trials, we have to have faith and keep working.
That worked for Selah in this case because we were blessed
to have a group of people that stepped up—both inside and
outside Selah—to help address the base-technology transfer
issues. So, there have been unexpected problems, but again,
we have been provided with the means to address those
problems. For this I am very grateful.
Interviewer
The last question is what advice would you give other
entrepreneurs considering a technology business?
Michael Bolick
Well, the first thing, the most important thing is to never
forget that your word is your bond.
Next is if you do not try, you will never know. I struggled for
some time before I could finally turn in my resignation and
walk away from lucrative employment with great job security
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and a great career path. I guess you could call that decision
a leap of faith. I do not know if we will make this all work,
but I know with absolute certainty that if I had not given
this a shot, I would have always regretted it and looked back
wondering what might have been.
Unless you can get to strong cash flow early, you are likely
to need to go out and ask other people for money. This is
not my favorite part of the job, but it is a necessary part of
the job. Make sure your documents are well thought out and
clean.
We are seeing a rising tide of entrepreneurial opportunity in
South Carolina right now. If you have the burning desire to
do this, listen to your instincts. Do everything you can to
build the right plan and team, but do not lean only on your
own understanding; be willing to listen. If you do, there are
a lot of people here that will help you.
Proverbs tells us that a wise man “sees danger and hides
himself, but the simple go on and suffer for it.” This reminds
me that not every idea is a winner. Some ideas are just plain
wrong. A really good mentor will tell you when your idea
stinks.
I have had quite a few of those conversations in the last
year and a half. Truthfully, I will not say that in every case
I completely agreed, but I listened, and hopefully I listened
well enough to make wise decisions as we go forward.
Finally, remember the difference between a lifestyle business
and a growth-mode business. Unless you can figure out a
way for your technology to be “it” for an extended period
of time, it is difficult to build a lifestyle business around
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technology. You have to be of a mindset that you have to
grow or die, but remember that you cannot grow so fast that
you outrun your cash supply. Focus on these conflicting
priorities, and you will have a great shop and will grow a real
business.
I say this last part with a silent prayer in my heart. We have
not gotten there yet. God willing, our team will look back
and see that we made a real business of Selah.
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Elizabeth Cates
Invenca

Elizabeth Cates is co-founder of Invenca, an advanced materials
company in the chemical and biochemical separations field.
Founded in 2007, Invenca emerged from work done at Clemson
University and is now located in Greenville, South Carolina. In
this interview, which was done in July 2009, Elizabeth discusses
Invenca’s founding, current work, and future goals. Currently,
the company’s work centers on developing new materials for liquid
chromatography and creating cost-effective separation products for
proteins and other large molecules.
— Ali Ferguson

Elizabeth Cates

Interviewer
So, how did your company start? Where did you begin?
Elizabeth Cates
Invenca got its roots in 2006 when Dr. Brian Morin, my
cofounder and business partner, went to Clemson to talk
with Phil Brown at the Palmer Science and Engineering
Department about some of the work that he was doing. Phil
introduced Brian to this technology at Clemson that used
fibers as the basis for chemical separations.
Brian examined the technology and immediately saw the
utility in it. Then, with a little more research, he realized
that he could build a pretty successful business around this
technology and decided to license it from Clemson.
For this type of work, you really need to have someone who
understands the chemistry behind the technology. I have
known Brian for 20 years; we went to high school together
and have kept in touch ever since, so when he needed a
chemist for this company, he called me up and asked me to
get involved. I came on board in late 2007 and launched the
company.
Clemson University has filed several patent applications
in this area, to which we have an exclusive license. The
technology invention is not commercially viable, so we need
to find the innovations that will make it a commercially
viable product. We are trying to find ways to take this
technology and really make it something that we can
manufacture commercially to meet commercial demands.
Interviewer
Okay, so what exactly is your technology?
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Elizabeth Cates
The technology that we are producing is a basis for chemical
separation. Chemical separation is done in the liquid state.
So, if you have a mixture of chemicals in a liquid, then you
can use our technology to separate them.
The technology itself is called High Performance Liquid
Chromatography, or HPLC for short. HPLC is one of the
most frequently used analytical techniques in the world,
second only to weight measurement and pH measurement.
It is used every day by thousands of chemists and
technologists worldwide to measure things like the purity
of the product that a company is producing, whether that
is in a pharmaceutical plant or a personal-care product
like hair spray. It is used in clinical testing to look for
disease markers and in drug concentrations in patient
samples (urine or blood samples typically). It is also used in
environmental testing, as a way of determining the presence
of environmental contaminates and quantifying their
concentration. As you can tell, HPLC is used very regularly
for analyzing the purity or composition of materials.
On a larger scale, the same principles can also be used for
purification. If we can isolate a compound and identify how
much is present in a given solution, then we can also isolate
that compound and collect it in order to have a pure sample
of the compound.
Chromatography is also one of the primary methods for
purification of biopharmaceuticals. Most of the vaccines and
over half of the drugs in the pharmaceutical pipeline right
now are based on protein structures, so the technology that
we have developed is suited very well for the analysis and
purification of proteins.
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Interviewer
Are there other companies that do this kind of thing?
Elizabeth Cates
There are a surprising number of companies that make
products like ours. The industry itself is about 50 years
old, so it is a well established industry. For an industry that
is fairly mature, there are a surprisingly large number of
companies. In a mature industry, you would expect to find
only a handful of companies present; however, the number
of companies that are making products in this area is well
over 200.
It is a vibrant industry that really loves new products and
new technologies. The small companies out there really focus
on creating niche and custom applications and developing
new applications; that is where Invenca fits in—developing
new applications.
Interviewer
So, is your product unique as compared to the others, or is it
just better?
Elizabeth Cates
It is a unique product. If we look at the HPLC industry
as a whole, it has historically focused on small molecules,
pharmaceuticals primarily: things like aspirin or
acetaminophen. The technology has evolved around these
small molecules because they comprise the bulk of the
current HPLC market.
However, as I mentioned before, the market for biotechnical
materials is growing very rapidly. Even in this economy, it is
still seeing double-digit growth, and like I said, more than
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half of the products in the FDA’s pipeline right now are
biologically-derived materials.
As it turns out, the characteristics required for the separation
and analysis of small molecules are different than those
for proteins because proteins are much bigger. It is like
comparing a marble and a beach ball. The aspirin is the
marble, and a protein, like some of the therapeutics used in
chemotherapy, for instance, is about the size of a beach ball.
Because of their different sizes and characteristics, proteins
behave differently in separations, so we are really focusing on
protein separations currently.
Interviewer
So you essentially make instruments to separate proteins?
Elizabeth Cates
Yes. What we make is called a column. They are about the
size of a pencil or a chopstick. The column is a consumable
piece that fits into an instrument. The instrument itself has
pumps to pump solvents through the system, and then it has
an injection needle to allow you to introduce a sample.
The column is where all the magic happens; it separates the
components in the liquid into different compartments, if
you will. Imagine that you have a tube lined with Velcro
and that you are going to throw tennis balls and golf balls
through it. The golf balls will not stick to the Velcro; they
will just fly through and will all come out in one clump. The
tennis balls, however, will stick to the Velcro a little; they will
lag behind and come out in another clump.
This is same principle behind chromatography. You get a
time-based separation of materials with the column doing
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the separation. The columns are consumables, but they can
be used multiple times. Most columns have a lifetime of
anywhere from three months to a year depending on how
much they are used and what is being put through them.
Interviewer
As a company, what challenges do you face or have you faced
in the past?
Elizabeth Cates
As an entrepreneur in a startup company, I have had a very
different experience than working in a large company. Prior
to this, I had worked in a medium- to large-sized company, so
if I had a question about legal issues, like patents or business
contracts, I would go to the legal department for help. If
I needed to buy something I would just fill out a purchase
order and hand it over to someone else who would actually
place the order. If I needed a website, I would just talk to the
IT department, and they would make the website.
However, as an entrepreneur, you do it all yourself, so you
have to be crafty about finding the right people with the
right expertise when you need them. Everything is, by
necessity, outsourced, so you do as much as you can inside,
but you have to understand the limits of your abilities and
know where to go for help in the outside world. Fortunately,
we have a lot of good resources available to us.
The Clemson University Research Foundation, CURF, has
been supportive in terms of helping us find connections
within the university and the entrepreneurial groups there.
In Greenville, there is the NEXT organization, which is run
through the Greenville Chamber of Commerce, and Brenda
Laakso does a great job of organizing meetings for the
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member companies. That group meets on a monthly basis
for a round-table discussion of pertinent issues, such as how
to find venture capital funding, how to do viral marketing
for your product successfully, or what pitfalls companies
frequently deal with. They are a great resource.
The South Carolina Launch! organization has been a
phenomenal resource for us as well, especially in terms
of making connections and helping us find the resources
that we need. So there is a great deal of assistance for
entrepreneurs to get things started, which helps make it
easier. I think for a lot of us, it is a rush trying to do it all;
we just have to get our fingers in everything.
Interviewer
Do you have other people working with you?
Elizabeth Cates
I do. Right now, Invenca has three employees. I am the
chief technical officer and director of operations. Mark
Housley is our CEO. He came from the same, medium- to
large-size company that I had worked for previously, and his
background is in new business development. He did a lot of
intraprenural work at this company, bringing in technologies
and building businesses around them. He has seen and done
it a lot and has built multimillion-dollar businesses around
new technologies like ours.
He also has the finance, marketing, and sales background,
while I have the technical and production background.
Between the two of us, we cover all of the bases. Then I
have a young lady working in the lab as a technologist who
actually handles most of the testing that we do.
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Interviewer
In terms of finances, how did you first get money to start
Invenca?
Elizabeth Cates
Well, the first way everybody gets money is through friends,
family, and fools, as they say. Our initial fundraising was
done through friends and family, and then it was extended
to the existing investors in Innegrity, which is our parent
corporation.
Innegrity is the majority shareholder in Invenca. They
contributed mostly non-monetary goods, and after that,
we received some funding from SC Launch. I have been
applying for state and federal grants and different research
grants to help with some of the technical development work,
and we are also currently raising funds right now for the next
year to help get us through the product launch and to scale
up.
We are also looking to private investing groups like the
Angel networks and some of the larger organized investment
groups. The American Chemical Society has expressed
interest in investing in our technology, and we are talking
to SC Launch! and other related groups about round-two
funding.
Interviewer
Is it difficult to get that money?
Elizabeth Cates
It is. It is a scramble, but it really forces you to be creative.
Two years or three years ago, it was so much easier to raise
money; everyone had plenty of cash, and it was almost like
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going to Vegas. Everybody was willing to gamble a little bit
on the slots, but that is not the case as much anymore.
Now, you really have to have a good story to tell people. I
think we are in a really good position, though because we
have a really great story to tell, and we have patent protected
technology that is new and different. It brings a lot of
benefits to the market in this particular growth niche.
Interviewer
That is great. Now, where do you see yourself and the
company in the future; what do you hope to do, or what are
your grand ideas?
Elizabeth Cates
Grand ideas. Every now and then, we come back from
something, whether it is lunch or a meeting, and we go on
about all of the things we would do if we had enough money.
Overall, though, my grand ambition is to make an impact.
Part of it is very personal because I am a cancer survivor.
Advancing this technology will allow researchers to develop
cancer therapeutics faster and get them to the market more
quickly, which ultimately helps society as a whole and is a
cause that is near and dear to me.
We want to be a good corporate steward, so we also approach
our work from environmental and community standpoints
as well. Community outreach is really important to us; we
work with local schools and the community to help raise
awareness about science and technology in our area and how
it could really be a big boom for Upstate South Carolina. We
really want to build a knowledge-based community, so that is
another one of our goals right now.
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Our ambition is to grow as a company. What you see in
our industry is that the major players in the market address
pretty much every market segment there is, but when it
comes to developing new technologies, they keep their
eyes out for what the small companies are doing. When
something starts to gain traction in the market, they start
looking for mergers or acquisitions.
Interviewer
Do you hope to do that or do you want to remain a separate
company?
Elizabeth Cates
I think for me, the thrill is in the building of a business.
Once the business is established and is in more of a
maintenance and organic growth mode, I do not think it
will be as exciting for me, and frankly, I do not think I am as
good at running a business in that stage. There are people
with different skill sets that are better at that sort of thing.
As such, I think I would be willing to hand it off one day, so
I can go off and do it again.
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Matt Gevaert
KIYATEC

Matt Gevaert is the co-founder and CEO of KIYATEC, LLC.,
which is based in Pendleton, SC. KIYATEC develops and
commercializes enabling technologies for the pharmaceutical,
biomedical, and life science industries. The company focuses on
advanced in vitro diagnostic capabilities for analyzing cell-material
interactions and drug discovery. KIYATEC lab-based technology
provides more accurate simulation of phenomenon inherent within
the living systems of the body. Accurate modeling of these dynamic
conditions provides opportunities for advanced medical treatments
and enhanced diagnostics. This interview was conducted in
August 2007 at the Clemson University Renaissance Center. Since
this interview occurred, the company has secured $175,000 in seed
funding and has established operations in a wet laboratory and
office space in the Center for Applied Technology (CAT) Incubator.
KIYATEC’s focus is currently on product development and
advancing applications for its 3-D cell culture technology platform.
KIYATEC hired its first full time employee, a Cell Culture
Scientist, in June of 2009 and was using its product internally
in laboratory experiments in August of that year. After securing
additional seed funding in September and closing the seed round
entirely, founders Gevaert and David Orr joined the company full
time shortly thereafter. The team will utilize the seed funding
to pursue product development and its demonstration in large
market applications in preparation for a Series round in 2010.
— Judith Campbell

Matt Gevaert

Interviewer
Tell me the story of how you started KIYATEC.
Matt Gevaert
I came to the United States from Canada to do my
graduate work at the Clemson University Department of
Bioengineering because of its reputation in bioengineering.
I had an undergraduate degree in chemistry, and I wanted
to get Master’s and Ph.D. degrees with a biomedical focus.
There were only a few such places to go with a chemistry
background in 1996 because most bioengineering programs
focused on the engineering side of things, but not so much
on the material side. However, Clemson has this 40 plus-yearold program in biomaterials and professors who wrote most
of the textbooks in the bioengineering field in the 1970s. So
to Clemson I came.
While I was a graduate student, I went through the
invention-disclosure process several times. If all of these
patents are eventually issued, I will be an inventor on four
patents as a graduate student on three different topics, which
is a little unusual.
Some of the technology transfer staff have kindly called me
prolific. I think I was just annoying. I was that guy who,
when they said as part of the patent process, “We will do
such and such within two months,” I would wait two months
and a week and then go back and say “Okay, what is going
on?” So, I got to know everyone in the Clemson patent
office (Clemson University Research Foundation).
I had invented some things that I thought were interesting
and would have commercial value. The first invention was a
co-polymer. If you have ever had stitches that go away, they
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are made of the molecule lactic acid. Lactic acid is produced
when you exercise; you get sore because of lactic-acid buildup.
It is a natural product, and your body knows what to do with
it. When lots of these little lactic acid molecules are knit
together, long chains form. These long chains make up the
plastic used to produce those stitches that “go away.” This
co-polymer could also have usefulness for incorporating
drugs into absorbable materials. A patent on this co-polymer
has already been issued.
The second invention, which was actually a catalyst of this
company, is a tool used in labs to grow cells in a certain way.
A patent on this technology has also been issued.
The third and fourth inventions relate to a very tough kind
of plastic that might be used in an artificial hip, knee, or
spine. It was the focus of my Ph.D. work, which was done in
collaboration with a company in Canada. The quick story
there is that with the blessing and support of my advisor
(who also had some money, which is important) I looked up
an old connection of hers, and said, “Hey, let’s do a project
together. I do not want money. I want you to teach me
how you make these really tough plastics, so that we can
deconstruct it and then put it back together in a way that is
biocompatible for use in medical devices.” So, that made up
inventions three and four. After graduation, I held a oneyear post-doctoral position at Clemson, working primarily
with the Canadian company on the plastic compound.
After that position, I worked at CURF (Clemson University
Research Foundation) on technology transfer projects.
But let’s bring our focus back to the inventions. Again,
invention two is a tool for laboratory use. I have a
friend, David Orr, who was also a colleague in the Ph.D.
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bioengineering program at Clemson and also had a
laboratory tool.
Around the summer of 2005, David and I had both invented
small plastic pieces that could be used in a lab to grow cells.
At the time, he had his MBA and was getting his PhD, while
I already had my PhD and was beginning to gain interest in
the commercial side of things. We were also good friends, so
we decided to go into business together.
We founded our company: KIYATEC. You might wonder
about the name. It is based on a Hebrew word, but we
mutilated it a little bit to make it an English word. The
Hebrew root word is “chayah,” with a C H. If you have
seen the famous movie “Fiddler on the Roof,” you might
remember them saying “La Chiam,” which means “to life.”
So, KIYATEC, after Anglicization, roughly means life
technology, or technology centered around life.
Interviewer
Tell me about how those ideas came about in the lab.
Matt Gevaert
I can answer this question for my invention better than I can
for David’s. My Master’s project was creating an absorbable
polymer, and then my Ph.D. project was creating a non
absorbable polymer. Both times, my committee said (and
reasonably so) “Talk about how toxic the material is. You
have to prove that you can put it inside someone’s body and
it will not poison them.”
The first time around with the absorbable polymer, I
stumbled into this problem: I wanted to be able to look at
how cells grow on this material. What I wanted to do was
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put the cells right on top of the material and see if they
would stick. If they did, I wanted to know how they grew
and how fast they multiplied. These types of answers are
important indicators of how toxic the material is going be.
However, the existing ways to address this problem were, in
my mind, not robust enough to give me the answers that I
wanted.
For example, a conventional method to test a material like
mine is to grind it up, soak it in a medium, and then take
that liquid and test your cells against it. That will tell you
whether it is going to leach out anything or not and whether
the leachables are toxic. This test is important, but not what
I wanted. There are some other ways people try to do this,
but few of them were suitable for my material. So, when
I did my Master’s thesis, I did not include any tests in my
results that were done exactly the way I wanted because I did
not have the method to do so. That was the catalyst of my
idea. One of my committee members was Dr. Karen Burg,
and after switching projects from my Master’s to Ph.D., I
said to her “I would like to revisit that problem. I have some
ideas on how we might go about solving that testing need in
a better way.” She said yes, and gave some other suggestions
as well. Between the two of us, we came up with a design.
The device that we developed is essentially based on the
design of a cell-culture “Petri dish.” If you have watched
the television show “CSI,” you will often see them looking at
cultures in a six-well Petri dish-type configuration (or twelvewell or twenty-four etc.). Dr. Burg’s and my invention is an
insert that fits on top of the Petri dish shape and holds the
plastic (or other material) to be tested down, so you can grow
cells on it. There were a number of variations that we could
have generated based on this design, but ultimately, we did
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not go with it but instead went with this (a 3-D cell culture
chamber).
The device has ports on either side going in and out, so fluid
can flow in two parallel paths. There is a little chamber
about the size of a pencil eraser. There is one on the top and
one on the bottom, and in between, there is a membrane.
You can grow cells in three dimensions in that chamber.
Instead of growing them in the Petri dish configuration,
which is two-dimensional, you grow them stacked on top of
each other in a 3-D configuration.
Cells grown in three dimensions behave much more like
those in your body since the cells in your body also grow
in three dimensions. When growing cells, you want to get
relevant and useful information, and when the environment
for growing these cells is more like it is in your body, then
the results of those tests are more valuable.
The 3-D cell culture device is based on David’s Ph.D. work.
His invention was also co-invented with Dr. Burg, and it also
went through the patent disclosure process. We both worked
with Dr. Burg as students independently of one another.
Their invention involved growing cells in a way that was
more physiologically relevant. In fact, his project started as
a project actually working with stem cells. Just to be clear as
far as that goes, there is no controversy relevant to his work;
there are many different kinds of stem cells, and we have
always worked with adult stem cells only.
For David’s Ph.D. project, by using the same stem cells on
either side of this barrier, he grew cells that changed into
bone on one side and cells that changed to cartilage on the
other side. The result was a little plug that was half bone
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and half cartilage. This would very valuable for people with
cartilage defects, say as a result of a car accident or some
kinds of arthritis. Cartilage is very hard to work with; it is
avascular and gelatinous, and it is not easy to get things to
stick things to it. This idea, then, has a lot of potential, but
it was still very far away commercialization.
But, back to the formation of KIYATEC. David had this
invention, and I had one similar to it, and we said: “Okay,
these are both technologies that we can commercialize
synergistically inside this company. In order to do this, we
will need a lot of the same things: injection molding and
incubators to grow the cells and to conduct a number of
tests on the materials and the process. And, we will need to
figure out a way to market and sell these devices.”
So, this was the formation of our company. It made a lot of
sense to us, and we were both excited. We both recognized
the value of doing it together instead of apart, so we formed
the company around these two technologies.
Interviewer
On what date did you incorporate your business?
Matt Gevaert
I believe September 1, 2005 was the legal day of
incorporation. The discussions started probably that spring
and went into that summer.
Interviewer
Did you hire a lawyer for your incorporation? How did that
process work?
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Matt Gevaert
We did, but since we were cash strapped, there was a bit
more to it than that. We did some research on possibilities
for finding money to help pay for business development
expenses, and we identified a program called SBIR Phase
Zero (SBIR—Small Business Innovation Research.) This
program provides small grants, I believe up to $4,000,
to help entrepreneurs submit for an SBIR grant to a
government agency. As part of the SBIR Phase Zero grant,
there is a list of reimbursable expenses that you can accrue.,
which includes legal fees. We applied for and received one; I
think our SBIR Phase Zero grant was about $2,000.00.
We asked many people we knew about lawyers who were
willing to work with startups and who might have reasonable
fees on the front end and were known to do good legal work.
While it would have been possible to do the legal work of
incorporating ourselves, we decided to hire a lawyer because
we both recognized that legal issues were not our strength.
The legal aspect of incorporating the business was something
that we did not want to make an early mistake on and then
dread finding later. Our initial legal costs were less than
$1,000.00, and the SBIR Phase Zero program supported
those expenses.
Interviewer
It sounds like the first part of the process was that you had
the idea to commercialize these two inventions and then you
received an SBIR grant.
Matt Gevaert
No, unfortunately we did not receive an SBIR grant even
though we applied for one. The purpose of the Phase Zero
grant is to encourage people to apply for an SBIR grant.
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Interviewer
And then what happened?
Matt Gevaert
While I was working a full-time job and David was
completing his Ph.D., we ended up submitting three different
grant applications that fall, which is pretty good productivity
for the first four months of a company. These proposals
were targeted to supporting either of the two inventions since
we did not know which one might be of interest to possible
funders. None of these proposals ended up getting funded,
but we were also able to develop our business concept further.
Interviewer
Were your proposals submitted to major agencies, such as the
NIH— National Institutes of Health?
Matt Gevaert
There are many departments under the NIH, and these
two technologies would appeal to different sections. We
had a strategy: this one fits best here; this one fits best over
there. We were competing against bigger organizations
and universities for these grants, and as I mentioned, we
did not get funded. But, in parallel, we were exploring the
commercial side of things. It was around the next spring
that we started talking to people about the different devices.
Interviewer
Can you elaborate about what “talking to people about the
different devices” means? Who did you talk to?
Matt Gevaert
We tried to figure out how we would go about making and
selling these devices. First of all, there is always the issue
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of finance. We needed capital, so we needed people who
understood that we could make money on these devices.
Then, we needed a way to get the products to customers,
such as through big distributors of lab apparatuses.
Therefore, we needed to know how these companies did
business and who our major competitors in this field were.
What we realized after exploring this industry is that we are
a “tools company.” We are not making a drug or an implant;
we are making tools for researchers. We found out very
quickly that many of those markets are pretty small.
In both my CURF position and in my entrepreneurial
position, I found that many individuals have clever ways of
solving problems in the lab. These lab solutions are good
ideas, they work, and they are often patentable. But, when
it comes down to it, there are not enough scientific labs
around the country, or even around the world, to justify
spending a lot of money to commercialize a product to solve
these problems. On the very extreme, if you are a very
specialized scientist and you work at one of only three labs in
the world that can do such-and-such research, if you create a
tool for that specific lab, you can see that the market size is
potentially three labs total.
Now, of course, it generally does not work that way, but if
you are going to raise money, you need to have a market
big enough for investors to have a chance of making a
substantial return back on their investment. This was the
issue with the first device, the one that I had invented. While
it was closer to commercialization and a simple patent on the
device was closer to being issued, the market was not large
enough to sustain a large outside investment.
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We thought we could get this device into the marketplace
and generate a revenue stream and then use these revenues
to develop the other device further. However, what we found
is that there was not a lot of investor support because of the
small market size. If we had a lot of our own money, we
might have gone ahead with that device because it could be
promising right now.
I recently received something in the mail from a Finnish
company who has a device that is pretty similar to mine, and
they are trying to get market penetration. However, because
we do not have that kind of capital, we need to talk to people
who can invest.
We could obtain money through government grants, which
we have pursued and are still pursuing, and then, there is
private money as well. There are tradeoffs between the
two. Government grants often take a long time to get, but
the money you receive is non-diluting. Government funds
also enhance your credibility because if you get funded, a
specialist has looked at your proposal and judged it worthy
of funding. But, government grants take a while to get. If
you apply for the grant and get funded, you do not receive
any money for another six to nine months, and in the
business world, that is a long time. On the other hand,
there is private money, which you can generally raise more
quickly, but an equity investment dilutes the ownership stake
of earlier investors. So, we were trying to strike a balance
between both.
In looking at the marketplace, we found a number of
possible uses of the 3-D cell culture technology. One
application would be for drug discovery. There are a number
of different estimates, but it appears that between $800
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million and $900 million is spent in production for each new
drug that comes out. There are a number of steps in drug
discovery that occur before these drugs reach clinical trials. I
am oversimplifying the process, but conceptually, companies
initially test new drugs with a very simple biochemical
assay. Then they might move to testing the drug on live
cells, cultured in ways like the one we just discussed. From
there, if it passes muster and everything else works out, they
would move towards testing the drug on animals to study
the drug’s toxicity and effectiveness. After these studies, they
would consider testing the drug on people. By the time the
drug is used on people, it has gone through a long process of
testing. On average, for every 10,000 new drug compound
candidates, only one makes it through. It is a long and costly
process.
Our invention allows us to grow a certain cell type on top
and another cell type on the bottom, which creates a 3-D
test system. Cells in this system behave more like cells in
the human body when interacting these different drugs.
Secondly the 3-D cell culture method, although it is not yet
standardized, is used in some form in many labs already. Our
product creates a way for multiple cell types to “talk” to each
other while growing in three dimensions, which is hard to
do using existing equipment.
I will give you a good example that I am preparing a
grant application for: Cancer. For cancer studies, many
researchers have said that previous 2-D cancer studies are not
meaningful because you have to grow cancer cells in three
dimensions to make them behave as they do in the body. If
you test an anti-cancer drug against cancer cells grown in
a 2-D environment, you might not be getting an accurate
answer of whether it will actually work or not.
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Another strong point of interest is liver cells. Drugs are
processed in the liver, but when they are, the liver may
potentially alter the drug; the liver might tweak it a little
bit into another compound entirely. It is important to
understand how that occurs. Does the drug become more
effective? Does it become less effective? Is it toxic?
So, what I am proposing in this grant application is to be
able to culture liver cells three-dimensionally on the top and
cancer cells on the bottom. Then, I would test this minibiological system using four drugs that are already known to
be significantly affected by liver-cell processing.
Two of these drugs are known to become more effective
when they are processed by liver cells, and you can
understand why this is important to know. The other two,
however, are known to become less effective when they are
processed by liver cells. If I can use this invention to test
these drugs and tell exactly how they affect the cancer cells
growing adjacent to them, post-metabolism by the liver, I
would be able to provide drug companies with very valuable
information. I will demonstrate this using four drugs that
we already know affect the liver in particular ways. By
implication, if we can test four drugs with this invention,
then we can test ten or 100 more drugs for which we
currently do not have answers. With this invention, I can get
answers cheaper and faster without involving people.
This is the essence of the technology. KIYATEC will
eventually make instruments with a lid that can be opened
in which ten to twelve of these little cubes can be plugged.
These cubes have conditions in which you culture cells: at
the right temperature, at the right humidity, and at the right
carbon dioxide level.
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We envision that drug companies will use this tool to
determine how effective a drug is going to be. I just gave
you one example of culturing liver cells with cancer cells.
There are a lot of different possibilities: if you are trying to
construct a drug for diabetes, you might want to culture
pancreatic islet cells, or if you want to test a drug to see how
much of it resides in fat cells, you could also do that.
Interviewer
Tell me more about the commercialization process, in terms
of discovering your market for this invention.
Matt Gevaert
I have sought to develop relationships with people engaged
in drug discovery, people who would understand the value of
this invention. They understand that we need better in vitro
assays to do drug testing. The drug people are saying, “Well,
show us. Prove that your invention can do what you say it
does.” So, this is the stage of commercialization at which we
find ourselves: needing to raise money to do proof-of-concept
studies for the drug application.
We have already proven the effectiveness of our other
application for the research market, but for this particular
market (testing drugs), we want to be able to show that it
works on known drugs first. The next step would be to test
it on more drugs: say, ten drugs for which drug companies
already have answers, but we (KIYATEC) do not. Then, we
will test the device on ten drugs for which even the drug
companies do not have answers. We have to demonstrate
the value for a particular application for each customer.
Risk goes down as time goes forward. Right now we are in
an area where they want to see the invention mature a little

ACORN 111

bit more. They want to see the invention’s effectiveness
more readily for these particular applications, and that is the
challenge. I think my immediate focus is going back towards
government grants because this is an interesting scientific
problem, and it will be valuable if we can show that it works.
A number of people have asked about whether they can
invest in the company. I want to hold off on that issue until
I get some of the other questions answered. I think that you
have to build value into your company to a point where you
can actually accept money. It makes sense for downstream
dilution issues. Many of the venture capitalists I know have
explained that it makes sense to prove the technology first
before taking outside investment money. So that is what I am
trying to do.
Interviewer
Did you do a business plan?
Matt Gevaert
Yes. I will give the credit to David for this. He was the
mastermind behind most of the business plan writing.
He graduated with his Ph.D. in the fall of 2006. He was
working full time with the company and dedicated his time
to writing a business plan, among other things.
We have an award-winning business plan. We entered and
won the Charlotte Five Ventures Business Plan competition
this last spring. We competed against teams mostly from
North Carolina. We made the top three among non- student
teams, and then went to Charlotte for a day, where we met
with review panels, had discussions, and engaged in mock
scenarios of investors and companies asking us about the
technology. Again, I will give David credit. He championed
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that process, and we came out with the win. So, we have an
award-winning business plan.
Interviewer
Did you find the business plan competition valuable?
Matt Gevaert
Yes. It has given us a lot of good exposure. Winning the
competition adds some credibility to what we have done. I am
still realizing the value of that. For example, we now know a
lot of business people in Charlotte. So, yes, absolutely.
Interviewer
Is there anything missing from the story?
Matt Gevaert
What is missing from this story is that after we won the
business plan competition, you should be asking yourself,
why I am sitting here, and not David, who I have mentioned
many times.
Picture the scenario that David, as a young entrepreneur, is
also married. He finished his Ph.D. in August, so now he
is with the company, but we do not have money to pay his
salary. This was a challenge of whether we could raise some
money, and get this money into the company in time to
actually start paying him a salary. He has a Ph.D. and MBA.
He has some very valuable skills, and at the end of the day,
we were not able to raise the money to have him employed.
So he has taken a job up in Indiana with “Cook,” a great
medical-device company that has need of a similar set of
skills.
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As a result, we have shifted from where before I was in the
passenger seat in terms of ownership and responsibility to
where I am now in the driver’s seat in terms of both of those
things. So now, it is up to me to lead things forward as far
as it can go, and this is what I am trying to do. But sadly, I
have to note that this region lost a great entrepreneur to a
job up in the Mid-West.
In retrospect, I think we were a ahead of the curve on a
couple things. If you look at the developing infrastructure in
this area for entrepreneurial activity, young companies like
KIYATEC are growing. So, there are options available now
that were not a year ago, which is definitely good.
I guess those things were not in place quickly enough for
our company, and/or we did not click into what was in place
soon enough to have made it work where David would still
be here. We certainly have had our struggles and learned
lessons on the way too, and I am still looking for that grant
or something else to get things going. I might also talk to
some investors in January. But either way, our goal is to
get some money into the company by next summer and to
go forward with developing the invention concept and its
validation and then to go from there.
Interviewer
I know some people are interested how technologies from
Clemson University are licensed. Since you have been
on both sides of the licensing process as both an inventor
at Clemson and as a licensor of this invention, could you
explain how does the process work?
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Matt Gevaert
Basically there is usually some upfront consideration, quid
pro quo from the company for the use of the asset “as is”:
early and often unproven but still representing something
in which the university has invested resources. Part of a
standard license also involves royalties, which people tend
to focus on, but royalties do not come into play until you
actually start making sales, which is downstream. Typically,
there is an understanding that these technologies often take
several years to commercialize. For example, there are no
royalty expectations on this technology any time in the next
year. If I did start making this invention and selling it, then,
yes, there would be some royalty expectations.
Interviewer
My sense is that there is a basic understanding that
technology commercialization takes a long time, and the
university is saying “let us put these patents out in the world
and have companies commercialize them” and that there is
a royalty if it works and sales are generated from the patents.
But probably most of them do not work. However, some
of them do, and these are the ones that provide revenue to
Clemson.
Matt Gevaert
Yes, that is exactly right. There is an understanding that it
takes time, and there is an understanding that most of the
patents will not work or be valuable in the market. The
university’s job, with which the technology commercialization
officers are involved, is to create the possibility that patents
generated at Clemson University are licensed by others and
commercialized.
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The goal is to create a good licensing deal that makes sense
for everybody. The deal should make sense for the company
who takes the technology in, and it should make sense for
the university who passes it out. For example, the university
is concerned that companies will license technologies and
not do anything with them. So, there are typically provisions
to ward against companies just licensing technologies and
sitting on them. Most licensing contracts have an annual
minimum companies have to pay to maintain the license,
or if the company has not sold the first product by a certain
date, then the license expires. Provisions like these are
certainly always in place as well. In licensing a technology,
we look to see whether the company is really trying, doing
a good job of commercializing the technology, and moving
things forward.
But they are also structured in a way that makes sense for a
young company that is not going to have royalties any time
soon. In addition, there are ways to offset the initial cost
required by a company for the upfront licensing fee. The
research foundation, for example, may ask the company for
equity in the business in lieu of a cash fee. In this way, the
university will be rewarded as part owners of the company.
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Charles Pringle
Andrew Clark
Brent Buckner
SensorTech

In the following interview, Andrew Clark, Chuck Pringle, and
Brent Buckner discuss the founding of SensorTech, LLC., a
startup company that emerged from research done at Clemson
University. SensorTech specializes in the development of a novel
contact sensing material that can be used in a wide array of
industrial applications. While doing research as a doctoral student
at Clemson, Andrew discovered a method for conducting electricity
through a polymer to create a sensing material. This research and
resulting technology became the foundation of SensorTech, which
Andrew and Chuck founded in May 2007. The initial technology
was used to create trial tibial inserts for knee replacements and has
expanded to include load cells and stent-testing devices. SensorTech
was originally based out of the Griffith Building in Pendleton as
part of a Clemson incubator but has since moved to a new facility
in Greenville. At the time of the interview the company was
working on negotiating contracts with the Applied Research and
Development Institute and the Department of Defense to establish
new uses for this novel material.
— Ali Ferguson

Chuck Pringle

Andrew Clark

Brent Buckner

Interviewer
Please introduce yourselves, and then tell me the story of
how you got into this business.
Chuck Pringle
I am Chuck Pringle, CEO (Chief Executive Officer) of
SensorTech.
Andrew Clark
I am Andrew Clark, CTO (Chief Technology Officer).
Brent Buckner
I am Brent Buckner, Director of Business Development and
Administration.
Chuck Pringle
SensorTech was started as an outgrowth of Andrew’s work
in the BioEngineering Department at Clemson. Andrew
went to Clemson for his entire educational career; he
earned his Bachelor’s, Master’s, and PhD degrees here and
graduated in May 2007. During the course of his graduate
studies, Andrew started to work with UHMWPE, which is a
high-strength polymer, and discovered a method to make it
conductive so it could be used in a variety of measurement
applications. Initially, he did some work centered on load
cells as they are used a great deal in industry. He also began
working on a “smart” trial tibial insert that is used in total
knee replacement surgeries. The patent is actually based on
this body of work. These inserts are becoming increasingly
important because the number of such surgeries is rising
steadily in our aging population.
In January, 2007, Andrew and I began discussing what he
wanted to do with his PhD after graduation. During the
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first half of 2007, we took advantage of an exclusive option
to license technology from Clemson University through
CURF (Clemson University Research Foundation). We
eventually began moving in the right direction to developing
our company and establishing our initial business activities.
Around the first part of July 2007, we obtained some space
in the Griffith Building in Pendleton, which is a CURF
facility for advanced materials and an incubator for startup
companies. We had to set up a lab space, which essentially
took up the rest of the summer because we had to identify
and procure the equipment required for our work.
The equipment started to arrive around the first of
September, and soon after, we realized that we would have to
leave the CURF facility due to lack of space. As of January
2008, we completed the move from the Griffith Building
to our new facilities in Greenville. Actually, we are having
our lab floor finished today, and we will be moving into the
space tomorrow. SensorTech truly is a startup just getting
into business.
Those were some of the first steps we took. We received
our initial funding from a $50,000 university startup grant
from CURF and SC Launch, and we also received some
money from friends and family. Our plan for the fall entailed
further technical characterization of our materials. This type
of characterization is a common technical task in the sale of
products and goods, so we put a good bit of time into that.
However, the material characterization process was hampered
a bit by our initial lack of space and by the few times we
relocated within the Griffith Building. So we had a few
stops and starts in the Griffith facility, which motivated us
finally to relocate here. I have to say that Andrew did a very
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good job during that time, especially because the work was
very difficult and we did not have a fully functioning lab.
Andrew’s initial work was so intriguing that we even had
some interest shown by outside companies during the study
period. People wanted to talk with us directly about what we
had, perhaps even before we were quite ready for them. We
were also encouraged by the load cell market research we had
done with Spiro International.
At the same time, we had some initial conversations with
ARDI, which is a technical institute joint venture of South
Carolina Research Authority and Clemson University. ARDI
is working on a R&D contract from the Office of Naval
Research pursuing solutions for naval material issues.
Through this relationship, we also became aware of a
program that they were working on in prosthetics. Long
story short, we have submitted a proposal to them to develop
a material for using in fitting prosthetics. It should be a
significant award, especially for a startup company. ARDI’s
interest further solidified our initial thoughts that our
material could be used in a wide array of applications and
would have significant advantages over existing products in
the marketplace.
Overall, there are still some medical applications that hold
promise, but we believe that our near-term success will be
to begin on the ARDI contract and, at the same time, add
additional resources in order to begin looking at load cells in
earnest. During the remainder of the year, those two things
will probably be our focus areas, trial tibial inserts and
stent-testing devices. We are very encouraged. That is pretty
much where we are.
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Interviewer
I have a lot of questions. First, can we start with some
issues about the technology? How did you decide on what
particular ideas or commercial ideas you wanted pursue?
Andrew Clark
Just common sense, I guess. We just saw where our
technology might fit and what its potential was. As a
research engineer, when you work with something for so
long, you intuitively know where your technology can go.
Brent Buckner
Well, I think one of the challenges that we are having right
now is that we need to concentrate on one major focal point
that will become our revenue driver. We know we have these
three focal areas (load cells, prosthetics, and smart trial tibial
inserts) pretty much locked in, but we need to decide in
which area we are going to create a functional product that
will produce revenue over time so we can develop and market
these other ideas.
We probably have 50 or so research and development ideas
that seem to come up on a daily basis. So our challenge right
now finding something that will generate a steady stream
of revenue for us, but we have to do a little more research
before we reach that point.
Chuck Pringle
I want to add a little something to what Brent’s saying about
the load cells and go back to what Andrew was saying as well.
In the course of this work in the lab at Clemson, Andrew
used load cells successfully in some of the testing that he was
doing. So, he became aware of their functionality early in
his research.
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Interviewer
Now, can you describe what a load cell is in layman’s terms?
Andrew Clark
Okay. A load cell is a device that measures load, like
mechanical forces.
Interviewer
So it can sense pressure—basically, pressure from an electrical
current?
Andrew Clark
Essentially, yes.
Chuck Pringle
Load cells are ubiquitous in industry. They are used in many
applications from load cells in your bathroom scale at home
all the way up to load cells weighing tens of thousands of
pounds for industrial purposes. Inside a load cell, there is a
device called a strain gauge, which creates the measurement.
The load cell is a device that surrounds the strain gauge and
enables it to conduct the current into an external device
that gives the output. Load cell technology has not changed
much in 30 years so there is incredible opportunity for us as
verified by our market research!
Interviewer
So a load cell is essentially a polymer with properties that
produce currents when pressure is applied, and then you
get a sense of how much pressure applied by measuring the
current. Thus, load cells can be used many applications.
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Chuck Pringle
One of the beauties of being in the Upstate is that there is
a lot going on here technology-wise that we can get involved
with, from work at the Clemson University International
Center for Automobile Research (CU-ICAR) to work of
the Greenville Hospital system. There are a number of
companies that work specifically with vascular technology.
We are also doing some work with CU-ICAR. After Andrew
finished up his initial graduate work, I would say that
there was at least a modicum of interest in our work from
mechanical engineering faculty. Some of those faculty
members have since relocated to the CU-ICAR campus, so
we plan to continue interfacing with them in the future.
Also, we have talked to Michelin and BMW about some
automotive-related applications. So those are examples of
things we will get to at the right point in time, but we are not
quite ready for that right now.
In the short term, we will be doing more evaluations on the
load cell. I should make one other point. The money that
we received from SC Launch also came with some resources.
Warren Weeks, who was the technical director at SC Launch
when we received the money, came to us to discuss our
product and its applications.
Fortunately, we will not be asking for money from external
investors for a while, which will save us some time and
energy. We want to make sure that we have a much more
solid story before we go to a group of external investors.
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Interviewer
Great. So, can you tell some stories about how you got
involved?
Chuck Pringle
I have known Andrew through his parents before he was
a student at Clemson, so I knew what he was up to at
Clemson. As he approached graduation, I went to visit him
to discuss setting up this business. We decided we would
make a good team because Andrew has the technology skills,
and I have a long-term set of business skills and some extra
time because I retired early from Fluor. That is how we got
matched up, and then Brent came on during the fall.
Brent Buckner
I am a former banker and finance person. Before I took this
job, I was working at a bank in Chicago and just got really
burned out because I was on the investment banking side. I
am originally from Greenville, so I moved back here and was
really just searching for something different.
I was looking at a couple of different opportunities, and
then Chuck and introduced me to the company and the
work they were doing. I was looking for something that had
a vision and ideas that I could get at the front end of and
really explore with the new company, and that is what we
have here. Everyone is very passionate about what we are
doing here, and that was something I definitely wanted in a
new job. As soon as Chuck called, I came in, and we started
working on an ARDI proposal. It has just been a blast
getting to do something enjoyable.
So starting up with a new company is exciting (and
sometimes stressful), but in the end, the reward is going to
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be great. So, that is how I got on board with everybody. I
bring a different side that I think is unique for this company:
we have a scientist, the guy with the idea; a veteran, Chuck
who has been around business for a long time; and me, who
brings the financial and sales skills. As you can see, we are
pretty well-rounded right now, and we are going to continue
to grow in the future.
Interviewer
What do you see as your biggest potential problems, and how
are you surmounting them? You might want to think about
the history of the problems the firm has encountered.
Chuck Pringle
Probably the biggest issue we have faced so far has been
the whole space issue. We really wanted to be part of the
incubator at the Griffith Building.
I would say that a lot of problems were avoided due to the
initial funding from SC Launch. When we started, the
whole startup company incubator picture in South Carolina
was in its infancy, and everyone (including us) was going
through growing pains. Since moving to our new facility,
we have missed having the camaraderie of the other startups
in the incubator. However, we have planned to meet with a
few of them, Selah and Tetramer specifically, on a periodic
basis and share stories and business opportunities. This
is important because we hope to do some symbiotic types
of work with both of these companies in the future, even
though it will not be quite as easy as it would have been had
we stayed in Griffith.
On the other hand, SC Launch has provided us with a set of
resource partners to whom we gave a presentation earlier on
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in our work. We will probably come back to them in the next
few months to get some of their advice and guidance, but
we will wait on that until we become a bit more mature and
understand our own issues better.
I would say the next issue we will face is the next level of
funding. We already have a fairly large contract that we
are negotiating now, but we have to stop-gap finance that
somehow, which is an issue that we will have to confront.
SC Launch! may be a solution for that, though. In addition,
in our contract, we also have people who are willing to pay
money for our product, so we have to evaluate some issues
related to that as well. We will eventually go forward with
external advisors and get some advice on how much money
we are really going to need.
I would say that if there was an error in judgment so far, it
was that we discounted the startup costs. We had different
kinds of startup costs than the usual company, though;
the whole lab and equipment is maybe a bit unusual. We
decided not to use lab equipment from Clemson. We might
have been able to do that but decided that it would have
been inefficient because we would have had to work around
other people’s schedules. So we bit the bullet and spent some
money to obtain our own equipment.
Also, let it be said that we did not do everything we wanted
to do. Andrew did a great job in keeping down the price of
equipment. We have fairly nice equipment that we are proud
to show anybody, but it is not top of the line. I would say
that Andrew’s got promise if he ever needs to pursue a career
in procurement because he did a heck of a job with the
pricing from our equipment vendors. So, hats off to Andrew
for being able to get that equipment for us.
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In Andrew, I think we have a technology guy who
understands his product remarkably well. On top of that, he
is not only a research guy but is also a very practical person
in many ways. He really put all this together. As a company,
we are very lucky to have him because he is very handy. As
he likes to say, he likes to find technology solutions to realworld problems.
Those are some of the issues that we are dealing with and
how we are dealing with them, at least from my perspective.
Anything to add?
Brent Buckner
We have the same issues that I guess most startup companies
have: deciding what equipment to buy; choosing what kinds
of computers we need; finding a location for our office;
finding funding; hiring new employees etc. These are the
types of things that any company would probably have
to deal with, and we certainly have them. These issues
challenge us on a day-to-day basis, but that is what you have
to do to run a company.
Interviewer
It is a nice story about a seed company. You are right at the
beginning.
Brent Buckner
Yes.
Chuck Pringle
We are, and it is very exciting. It truly is. I mean, one of the
things that turned me on to this work goes back to when I
was working with the South Carolina Research Authority
(SCRA) where I was a board member and chairman. As
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I was exiting the chairman’s role, we were beginning to
plant the seeds for what is now SC Launch!, so I was always
interested in the subject of what goes on with research and
how a company moves on to the “real world.”
Starting this company was really a blending of my business
and program and project management skills and Andrew’s
technical skills. This blending resulted in the ARDI
contract, which is a significant piece of research for Clemson
University and for the upstate in general.
I was excited about the prospects for SC Launch!, and being
where I was in my station in life, it was a no-brainer to work
with someone who was passionate about what he had found
and about bringing it to life. Also, there were some realworld applications that we had already seen relating to what
he was working with, so I knew that this work was not going
to be research just for research’s sake; this is an application
that we are continually discussing and moving forward with.
Andrew Clark
I think that growing in Greenville is also very uplifting,
especially after having gone to Clemson. It is great to see
how much excitement and work is going into companies in
the Upstate and in South Carolina in general. There are a lot
of good things going on here that make what we are doing
even more exciting because we know that we have people
behind us that want to see industries come into this state
and make a difference. I think a lot of good things are going
to happen in years to come, especially in Greenville.
Chuck Pringle
In a year or two, we would really like to be a poster child for
startups in Sough Carolina. That is another of our goals.
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Interviewer
It sounds like you are really close. One more investment
here, one more project, and you have it.
Chuck Pringle
Yeah, well, this is a significant project for us, and we are just
hoping that everything works out.
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John Ballato
Earl Wagener
Steven Foulger
Dennis Smith
Tetramer, LLC

John Ballato and Steve Foulger are two of the four founding
members of Tetramer, LLC., and Earl Wagener is the company’s
CEO. In this interview, the three men tell about the founding of
this faculty-based startup company and the unique challenges they
faced along the way. Tetramer was established in 2001 when four
Clemson faculty members from different engineering and technical
backgrounds decided to combine their knowledge and research
interests to develop specialty polymeric and oligomeric materials.
The company’s current research and development is focused on
polymer fuel cell and gas separation membranes, biorenewable
resources, piezopolymers, and optical polymers. Tetramer’s research
endeavors and unique products have enabled them to make
strategic partnerships with larger industrial companies, including
General Motors (working on fuel cell technology) and Cargill
(creating renewable biomaterials). Since this interview in,Tetramer
has also created strategic partnerships with Membrane Technology
and Research and Draka.
— Ali Ferguson

Earl Wagener

Steven Foulger

John Ballato

Dennis Smith

Interviewer
Tell me the story of how you got into business.
John Ballato
I love telling this story. There are now three of us professors
here at Clemson University all working in different
departments: me, Steven Foulger, and Dennis Smith. I have
been here ten years, and I was hired into what was then the
Ceramic Engineering Department.
The next year, Dennis Smith was hired into the Chemistry
Department, and the year after that, Steve Foulger was hired
into what was then the Textiles Department. Through a
series of interesting circumstances, we realized that we had
a lot of complementary things in common in terms of our
research interests.
We had a chemist, an optics person, and a physicist.
Originally, we had another partner, but he is no longer here.
So, initially, we were just these four junior faculty from four
different departments who really did not realize that it was
not a typical thing in universities for people in different
departments to talk to one another. At the time, we thought
that was common practice. We realized later on that it was
not, but we still began to share resources, laboratory space,
and equipment.
To make a long story short, these four people from essentially
different walks of academic life came together because we
were much more effective in doing the research we needed
to do together. As we began working together, we had no
upfront thoughts about creating a company; we were just
junior faculty trying to get promoted and tenured and were
doing what we thought we were supposed to be doing. First
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we wound up founding a research center, COMSET, which
has been very productive, and then we established Tetramer
not long after that.
So, we did our research, published our papers, and went
to conferences to present our work. As that work became
better known, we were invited to speak at more and
more conferences. After a few years of speaking at these
conferences, people from various companies started coming
up to us after our talks and asking us where they could get
some of our material.
Being junior faculty, we did not know any better and ended
up just giving these people samples of our material to test.
We did not realize that we were essentially testing markets
that really did not exist at that point. Shortly after that,
Dennis suggested that we start a company because there was
so much commercial interest in our materials.
I think that is how many companies like ours start. We did
not go in necessarily thinking about spinning out a company;
we simply knew we had something of value, and there
ended up being a market pull for the materials that we were
developing at Clemson.
Earl Wagener
I think one of the pieces to the formation of Tetramer is that
Dennis, who was at Dow Chemical for about eight years, had
industrial background. So, one of his natural thoughts was,
“Hey, we can make this stuff and sell it.”
John Ballato
We began thinking about this idea of spinning out a
company, and the first thing we did was contact Caron St.
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John at the Spiro Center. She gave us marvelous advice as
far as what to do, what not to do, whom else to talk to, and
what steps we should take, especially as faculty members.
When we were beginning to set up the company, there had
been maybe one case in which a faculty member had actually
created a company, and there were some other horror stories.
There are a lot more guidelines in place now to protect
faculty and other people internal to the university when they
want to take their ideas outside.
In many ways we were charting unknown waters, but this
was something we wanted to do because there was interest in
our materials and because we liked working together.
After speaking with Caron, we found a lawyer and created
the LLC (Limited Liability Corporation), Tetramer.
Somewhere, I have all of these bar napkins on which we
diddled out different names, and then we searched them on
the Internet to see if they were taken. The etymology of that
word came from “tetra,” which means “four” (because there
was four of us), and “mer,” which is the root of the word of
“polymer” (because we work with polymers).
Anyway, Tetramer was born out of this market pull for the
materials that we had developed and are still developing at
Clemson. Their performance was superior to many things
that were on the market at the time.
The most important thing to the success of the company
to date has been Earl Wagener. In our case, we liked being
faculty members; we were good at being faculty members, but
we are not good at running companies because we do not
know anything about it. Well, Earl does.
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Steve and Dennis have industrial experience, but working in
a research lab for a massive company is very different than
being the CEO of a small startup company. So, the best
thing we ever did was to get things started and then get out
and give the reins over to somebody who actually knew how
to run a business.
Interviewer
You said you never really got out, though, right?
John Ballato
Right. We are still involved; we just handed off that part of
the business to people who actually know how to manage
a company. That is another pitfall that a lot of faculty fall
into: they see dollar signs in the possibilities of spinning
off companies not realizing that very infrequently do those
dollar signs ever materialize or at least not to the magnitude
that they think they will.
Many faculty members and most people in general, have
egos that make them think that the work they are doing is
the best out there and that people are going to give millions
of dollars for their products. However, they have no idea
about the other dynamics involved that make a product
or an idea valuable or not. So, they have these grandiose
ideas of spinning out companies, making their fortune, and
retiring on a lake somewhere, but it never happens. Very few
people that get into academia actually make the transition to
running companies. As a result, our decision early on was to
find someone to run the company because we knew that we
could not do it.
Low and behold, we found Earl Wagener, who is the perfect
Clemson man for the job. Earl was born and raised in

ACORN 141

Clemson, and his grandfather was in the first graduating
class at Clemson and one of the founders of Clemson’s
Chemistry Department. Earl earned his PhD here as well
and just loves South Carolina in general. He definitely
bleeds orange and wears it.
Earl Wagener
The situation was exactly that. I earned my degree here and
really wanted to stay in the Southeast. Initially, I got a job at
Milliken. I thought I had nailed it right on because I looked
really hard: I looked in Atlanta; I looked in Columbia; I
looked in Knoxville; I looked all around.
I got the job with Milliken in Spartanburg, but two weeks
later, they fired me because they had such a massive layoff
that they just said they could not use me. So, plan B was to
go to Dow Chemical up in Midland, Michigan.
I viewed the Midwest as this vast, cold, white tundra, but it
was my only choice, so I left the Southeast, went to Midland,
and worked at Dow. As it turned out, I loved Midland. My
philosophy is that you can enjoy anywhere you go if you take
the attitude that it will be a great place.
I worked in Midland at Dow’s central research area and
learned some background about the fundamentals of
polymer chemistry. Then, Dow offered me a job to set up a
lab in Walnut Creek, California, which is near San Francisco
and the Bay Area.
When I left Michigan, everyone kept telling me that my
career would tank because I was leaving the center of Dow
Chemical. I just looked at them and said that it would not
be bad out there and that I could help the company grow.
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The Walnut Creek lab was called Discovery Research,
and we were looking at new things like artificial kidneys,
membranes for gas separations, new polycarbonate-type
structures, and that sort of thing. We also wanted to
establish a lab in Japan, so I spent a fair amount of time in
Tokyo, and we eventually set up a lab in Gotemba as well.
That was a neat experience because I got to learn about a
different culture and how research was done in Japan.
I was in Walnut Creek for ten years, and then I got an
offer to go to Europe. My family and I lived in the middle
of Europe, outside of Strasburg or Baden-Baden. The
idea was for me to help Dow take the entrepreneurship
side of the company into Europe and do new things. So,
I was out looking at acquiring companies and different
technologies. Then I was told that it was time for me to get
back into the mainstream of Dow. So, I was sent to Texas
and headed up the group called thermosets, which worked
with polyurethanes and plastic. I had a pretty high-level job
at Dow while I was in Texas, but my wife developed a mold
allergy while we were there, and I told Dow that I had to
leave because my family life was in trouble.
I look at my career as having three foundations: my work life,
my personal life, and my spiritual life. A lot of people think
that entrepreneurs have to burn both ends of the candle all
the time, but if you do that, you will be a workaholic, and
you will burn out. And if you burn out, then you will not
have the sensitivity to motivate and enjoy people or help
them get through the tough times.
So, we moved to Chicago, Illinois where there were not many
mold spores in the winters, and I was back in the Midwest
shoveling snow again. I worked for ten years as the Vice
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President of Research and Development for a company called
Stepan, which is a specialty chemical company. They wanted
me to set up their European operation, so I was doing
that when Dennis called me up and said “Hey, we have a
company down here…”
Also, there is one thing that I forgot to mention about Dow.
While I was there, I was asked to be part of what is called the
Dow Capital Investment Finance Group. I was the research
component of this group that went out and invested Dow’s
money into other companies. The stipulation for these
companies was that they had to have some way of tying that
money back into Dow in order to create a synergy with Dow
that would make them more money.
During this time, I got to see how a lot of small companies
operated. I saw just how tough it is, but I also enjoyed seeing
how much they liked what they were doing. They barely had
ten cents to make it to the next day, but they had the attitude
that it would work. I always wondered, “Could I ever do
that?” I could not have managed it during most of my career
because I had a family to raise, but then this opportunity
arose, and here I am.
John Ballato
It gets better. So at that point, I did not know Earl, but
Dennis got his PhD in chemistry at the University of Florida,
and his advisor was Earl’s brother. Well, Earl’s brother
actually got Dennis a job at Dow through Earl. So when
Earl decided to retire and move back to Clemson about seven
years later, Dennis decided to return the favor by asking Earl
to meet with us two days after he had officially retired.
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The company was about a year old at that point, and
we ended up getting everyone together at a coffee shop
downtown where Loose Change is now. We just told him
about our company and what type of work we were doing,
and the rest was history really.
Earl Wagener
While we were having coffee, we talked about a lot of the
projects they were doing, but the thing I looked for was the
dynamic between these guys. They could speak the truth as
they saw it with each other. If they thought something was
right or not right, they would say it, but in the end, they liked
each other. That is what you need.
You cannot have a small company and have one person with
the attitude that he is going to take over the company at the
expense of the other partners. That was not the case with
these guys. It still is not the case, even though it is becoming
more difficult for them to spend time with the company with
their growing careers in academia and everything else.
Anyway, we looked at the products and asked ourselves what
had been done before and what we could do. My natural
instinct kicked in, and I told them what the critical values of
their products were had how we would evaluate the product
in industry. We sorted through each product and decided
which to keep and which to let go of.
We wound up with basically four platforms that were really
interesting. When you are a small company (we only have
eleven people now), it is tough because you get fewer at-bats.
So you want to avoid going for the home runs at first and
stay with the smaller stuff.
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Essentially, from a career standpoint, you have to get
back to zero, and it is good for you; it is renewing at many
levels. Small companies usually last two-and-a-half years,
but we are now on our sixth year and still going strong,
and our revenues are increasing. In fact, we just received a
notification today that we are receiving another half million
to continue our work.
We deal with big companies like General Motors, for
example. General Motors is making a fuel cell car, and we
are in line to make the fuel cell membrane for that particular
car.
John Ballato
You also have to realize that there is going to be some risk in
things that are new. In many ways, we got into things that
really had nothing to do with our expertise. We have our
material and know about that, but there are other aspects of
the business (like using Linux, for example) that we do not
know anything about. We believe that our material is going
to work.
Earl Wagener
In addition to working with General Motors, we still
have the optical side of our work. We coat fibers for high
temperatures and that sort of stuff, and we are looking
into other optical materials as well. For example, Sony is
interested using our polymers as part of their DVDs.
We are also looking at piezoelectricity, which involves
taking a material and stressing or bending it until electricity
is created by the tension. Or, you can put electricity in
the material, and it will bounce up and down; that is the
technology behind speakers, for example.
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We have found a way to make piezoelectricity six times more
effective using our polymers than anything that is out there
now. The fact that we all have backgrounds in different areas
helps tremendously because we can go to each other and say,
“Does this really make any sense? Is this worthwhile?” And,
we can tell each other exactly what is going on.
Then, there is the renewable area, which is going to be big.
We are looking at taking renewable materials and putting
them into industrial chemicals, like shampoos and plastics
for example. We want to find a way to convert soybean oil
and vegetable oil and are actually working with a company
called Cargill, which is the largest private food company in
the world.
Now, the neat thing about all this is that we have created
twenty-five jobs. We have eight PhD-level jobs in South
Carolina, and we are going to keep on creating jobs. While
eleven jobs is not a lot, if we get the sales we have projected
and the grants we have applied for, we are going to have five
more jobs next year.
John Ballato
As faculty, we initially started our work with research grants
from the National Science Foundation and the Department
of Defense. We only had a little “bubbler” in the lab and
were just making small, amounts of our materials, just
enough to take some measurements, write these papers, and
go talk about our work.
Fortunately, for us at least, the devices that generally use the
material only require a small amount. We had a material
that was very high value but very low volume. So, we did not
need tanker cars worth of material, which was part of what
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helped us get started. We did not have to go into developing
a commodity-scale material. We could get away with
something that was just very high value
So, Dennis, being a chemist, knew a gentleman who started
a company at the University of Texas at Austin that made
planar waveguide devices. Planar waveguides are to light
what integrated circuits are to electricity; they route the
optical information around to be processed.
The plastic that we developed was superior to what was
available for the types of things that they needed to do. After
doing the math, we realized that we were capable of making
the materials they needed because it would be done on
such an elementary scale; all they needed was a thin layer of
plastic that they could carve up, and we could handle that.
This was all around 2000 or so when the telecom bubble was
just getting bigger and bigger. We were very excited because
this company that we were making materials for was going
to talk to Intel, which was essentially ready to make an
investment. That meeting was schedule for September 12,
2001.
We all know what happened the day before, and that was
the end of everything: no more investments; markets fell;
telecom’s bubble burst. That was the end of that, and we
were just sitting there thinking “Well, good thing we have
faculty positions to fall back on.”
About a year later, there was another company in New Jersey
called Lightspan that was doing similar work and producing
planar waveguides as well. We were very excited because we
thought that our material was really going to revolutionize
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the field. But then, the head of that company, David
Stone, died suddenly from a brain aneurism. There went
the company. Again, we were thankful to have our faculty
positions to fall back on. Really though, had either of those
opportunities worked out, we would have been in trouble
because we would have done okay for maybe a year, but we
could never have scaled up beyond that. We would not have
known how to do it, and we would not have had the capital
to do it either.
We probably would not be around if those first couple of
things had come in. We needed to start small, so we just
kind of began bootstrapping these other things little by little.
Interviewer
Which means you were getting money?
John Ballato
Yes, we received money early on through small sales, testing
the market, and small research grants.
Interviewer
Well, if people were really curious about your work, would
they give you money?
John Ballato
Yes. Actually, the day we went down to the lawyer to set up
the company and sign off on all of the paperwork, we had a
$20,000 check from a company interested in our materials.
At first, researchers just wanted to test our material to see
if it would work for their specific applications. They would
work for their specific applications. They would say that
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they just wanted a kilogram of our material to make some
prototype device to see if it was what they needed.
So, we used the $20,000 check that one such company gave
us to start up our own company and to purchase some scaleup equipment and other supplies. Then we took advantage
of SBIRs, or Small Business Innovation Research grants.
Now, there are a series of other grants, contracts, and monies
that are coming in.
Earl Wagener
In terms of research, South Carolina needs to do a lot
better. These SBIRs are basically the U.S. Council of
Competitiveness’ way of making sure that innovation keeps
going in the United States.
These awards are $100,000, but the chance of being awarded
one is only 8 percent. Almost every time there is a call out,
which is twice a year, there are 3600 proposals submitted,
but only about 200 are awarded. Eight percent is not too
great; however, we have been awarded 13 SBIRs out of the
16 we have applied for because Clemson’s technology is
excellent.
We have a tremendous business engine inside this university,
but it really is not being tapped. We can do a tremendous
amount with it, and there is just more and more research
that can be done.
We already have a fairly decent reputation inside NSF
because of our track record. Researchers from all over the
United States apply for these awards. We are competing
against California, Michigan, Massachusetts, etc., all of the
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big engines for innovation, and we hold our own with them
very well.
In addition, we work with many companies and have signed
joint development agreements with them in return for
funding, for example, our arrangement with General Motors
for fuel cells. In return, we have joint patents, which protect
our ideas and allow them to have exclusive use of the patents
in the automotive area.
Fuel cells will also be used outside of the automotive
industry. They are used in houses, fork lift trucks, laptops,
and that kind of stuff. We have the right to take the
technology that has been jointly developed between our
company and GM and sell it in the non-automotive area.
We would then have to pay the other companies, like GM,
a royalty for the joint patent, but we have the right to go
explore that.
So, as a small company, you need a partner. You cannot do
it all yourself. You have to go out and sign joint development
agreements and that sort of stuff.
Interviewer
When did the business start to push in terms of product?
It seems to me that people wanted your product before you
were necessarily ready to give it to them.
John Ballato
Sometimes, it is just a combination of both a pull from
companies and a push on our end. We got started because
there was a pull from companies wanting our product. The
push began, essentially, to move into things like the fuel cells
and these gas separation membranes.
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We had a material platform that we knew worked for this
one application. That is why there was an initial attraction
and people were pulling it out of us, but we knew that we
could do more with the material than what we initially used
it for.
So, we began working with the material that we had
developed for one application and looking at it for other
things, and then we began trying to push that towards GM
and other companies.
Earl Wagener
For example, Nafion membranes from Dupont are the
standard materials used in the chloralkali and fuel cell
industries, and the companies that produce these materials
are huge, global manufacturers.
We sent some competing materials up to GM and told them
to test them to see if they worked as well or better compared
to these other materials. We did a few tests on it ourselves
and gave them our data, and they said “Well, if we can reuse
that data, we might be interested.”
The material actually worked quite well, but all GM could
say was “How in the heck does a tiny company, in South
Carolina of all places, outdo Dupont?” And I said, “Good
question. Come on down and find out.”
There is research proving that companies that startup at
universities last a lot longer than their counterparts who go
it alone. Here is the arrangement that creates a win/win:
because I am licensing technology from Clemson, I have
access to their analytical resources and equipment—for a fee
of course.
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We brought GM down and showed them that we have the
technology and capabilities through Clemson to compete
with larger companies. We took them through AMRL and
showed them how we were doing the polymer fundamentals
and understanding the kinetics of the polymer, how we put
the polymer together, what a block copolymer looks like, how
we actually sulfonate it, what type of yields we were getting,
and so on. They were impressed by our work and decided to
bring down the next level of people, and I knew that once we
got to the people in Detroit, we were in.
John Ballato
So, how does a company like Tetramer compete with
Dupont? Well, we showed them that the Clemson facilities
and that we have equipment that is as good, if not better
than, what Dupont has, especially in the areas in which we
work.
Earl Wagener
The resources these Clemson faculty need to do their work
are expensive, but they can get this expensive equipment
because they are good. They submit good proposals, so the
synergy begins to work. Clemson makes Tetramer look good
by providing resources, and Tetramer makes Clemson look
good with its talent and success. A lot of that talent comes
straight from Clemson; over the years, we have had about 19
people work for us, and about 90 percent of them came from
Clemson.
John Ballato
That is the loop coming full circle. When Earl graduated, he
could not find a job in South Carolina. Now, a lot of our
graduates can actually stay in the state through companies
like ours.
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Earl Wagener
It is by no means easy. We are always looking for more
money. Right now, we have SBIR money, but about 40
percent of our other income is starting to come from other
places. Some of it comes from General Motors, and Cargill
is purchasing a lot of materials directly from us to help them
work with some Nobel-Prize-winning technology out of
Caltech.
John Ballato
For small companies, especially, you can never really be sure
where the money will come from. I mean, you have so much
money in the bank, and you have payroll. One month,
you may be fine, but the next month you may have to start
worrying about bringing in more revenue.
Interviewer
So what was the most difficult challenge you faced as a
company?
Earl Wagener
I think one of the hardest things we had to deal with was
product liability insurance. The first time I sold some of our
material, the buyers asked about this insurance because all
big chemical companies have it. I figured I better find out
about that.
I called several different insurers that the bigger chemical
companies use, and they basically said, “Let me get this
straight. You are a three-person company, and you want to
sell chemicals right after 9-11. These are chemicals, right?”
I tried to explain that they were plastics, but chemicals are
chemicals to these people. They asked us questions like
“Does your stuff burn?” or “Will it explode?” Of course the
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answer to these questions is yes; they will burn and, under
the right conditions, they will explode.
Well, they basically said that they could not risk insuring us
because we might be a little terrorist group setting up a bomb
operation. It took me 18 months to find a small company
out in Seattle that would actually sell us insurance, and
it was from a guy that I knew from Dow who had broken
off and sold insurance. We had to get two million dollars
worth of insurance, and it cost us an arm and a leg. It cost
us $8,000, and we had not even sold anything yet. But, we
had to get it; whether we were going to sell 10 grams or 100
grams, we had to have product liability insurance.
The second challenge we have faced was finding quality
health insurance. It is ridiculously expensive. We went to
the Small Business Administration and said, “Okay, SBA,
you have a pool of small companies. We want to join that
pool so we can get lower rates for insurance.” No way. It
does not work that way. Even if you are in a big pool, it cost
much more for a small company to get health insurance than
it does for a bigger company.
So, each one of our employees goes through Blue Cross Blue
Shield, and it costs us $800 a month, but the insurance is
really not that great. We would like to be able to get into the
state employment system as part of a start-up in an incubator,
but that has not happened yet.
Interviewer
You talked about an exit strategy in terms of exiting everyday
management. Did you have an exit strategy before you
started the business?
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John Ballato
We did not have a strategy up front per se. I mean, the
strategy was simply that we knew we had to find somebody
who actually knew how to run a business, and it was not us.
So, the strategy was the realization that we could start up this
company. We could be technical directors, but we do the
best work when we are in labs at Clemson innovating and
working with our students. If we did not have this company,
we could help drive technology, but having an exit strategy
in that sense was the realization that we are not business
people. We had to find someone who was.
Interviewer
So, are you still the principals of the business?
John Ballato
Yes, that is right. So, the four of us all have equal shares
in the company, 25 percent shares. So, yes, we are the
principals, and we own 100 percent of the company.
Interviewer
That is why I was curious because the next question I want
to ask is why did you even start a business? Why not just
license out your materials?
John Ballato
License to whom? There was not anybody else. The polymer
technology was essentially one that Dennis brought with him
by and large from Dow Chemical.
You can actually get into the polymer itself with Dow;
however, for a company the size of Dow Chemical, this
size business is of no interest to them because it is too
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low volume and too low revenue. For a startup company,
however, it is a great opportunity.
We were innovating on an existent polymer; it just was not
sufficiently big enough to attract Dow, but there was this
market pull. So, we spun out the company to fill the gap
that existed.
Earl Wagener
Part of the issue is when you have a product that you have
to develop. It has to have an application because most
companies are not going to buy an idea that does not have
a patent, and many times an idea takes three years to get a
patent for.
So, if you license your idea, it does not have a lot of value
even though people like to think it does. A technology
transfer group will do what you are talking about; they
will just license it, and the average licensing is low, around
$2,000 or $4,000. There are a few homerun ideas that can
succeed going this route, but they are very rare. You really
have to develop mores applications before an idea has value.
If you look at product development as a five-stage process
with stage five being commercializing, you do not know the
value of the product until you are in stage two or three. You
may have a great idea that you are able to patent, but you
do not know if your product is valuable until these stages
because you do not have a customer yet. Your product is not
worth anything until your customer tests it and says, “I got
the same answer you did.”
This is what happened with us when we worked with GM.
If they had gotten one bad number, we would have been out
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of the loop, even if their technician hooked up the machine
wrong or the test was run incorrectly. To them, we are just a
tiny little company with another membrane.
Interviewer
Did you ever think where you wanted to go in the future?
Did you ever think that if you reached a stage with a certain
number of products or product sales that you might want
to ramp up, build a plant, and produce your products on a
larger scale and maybe license out to larger companies?
Earl Wagener
Yes.
Interviewer
So, where do you see the company: as one that is going to
license to larger companies to make these kinds of polymers,
or do you see yourself in that business?
Earl Wagener
All of the above. Okay, the materials that are PFCB oriented
are high in value but small in volume, so we will definitely
ramp up and make those. Basically, we can take care of
making what we need with a 50-gallon reactor, and since we
are selling it for $10,000 a kilo, we are going to make a lot of
money. We are in great shape in that area.
In the renewable area with Cargill, we are more on the
intellectual-property side because they want about 10-20
million pounds of our material. We will make the first half
million or million pounds, and at that point in time, we will
ask Cargill if they want to take the product internationally
and start to manufacture it because they have a lot of
catalysts they can do that with.
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Or, we will ask ourselves if we want to stay locally. South
Carolina obviously went out of the textile business a long
time ago, but the residual specialty chemical companies
that made the dyes and chemicals to treat the fibers are still
around. In fact, there is one such company over in Easley
called Ortec that we have talked to, and they would love to
scale up to the 10- to 20-million-pound range.
We could carry it up through that level because at 20 million
pounds, Cargill will still think that the material is in an early
stage of development, but we could make a lot of money from
that. So, the differential is between being a company like
Cargill, which some people have estimated is a 100-billiondollar company, and Tetramer, which is maybe a one-milliondollar company. To them, a million dollars is lost in the
rounding in terms of revenue.
So, we fill that range. So, yes, for one of the products, the
specialty plastics, we will go ahead and make it. For the
others that start to become high volume, we will begin to
manufacture them, and then at some point in time, we will
probably have someone else manufacture them and take
about 3-4% of what they sell.
We have had to think about this type of strategy for each of
our products, but we have to get out of stage two and three
to find out what the most viable strategy is: if we want to
manufacture in large quantities or if we want to stick with
smaller quantities.
Interviewer
How do you deal with competing technological interests?
How do you choose between these different avenues and
technologies?
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Earl Wagener
As John said, the pull from the optical area looked very
interesting to begin with. So, that was initially our defining
technology, which is called PFCB technology. It is very
versatile stuff, and you can make a lot of different products
out of it.
But, that area essentially crashed and burned, and we
had those incidents that John talked about how the two
companies went belly up and could not pay us. Several other
companies did the same thing. So we decided that maybe we
could go get a little bit more money in order to look at Steve’s
technology a little more closely. We got an SBIR to do that,
all the while hoping that the optical industry would come
back, but it really did not.
It is coming back now, but at that time we had to ask
ourselves what other things our technology could do.
We did not shift over into something like polyimides, or
polycarbonates, or something totally different.
That is when we got into fuel cells. We sat down and talked
about fuel cells, how they are structured, and what materials
are used in them, which got more ideas flowing. We decided
that our technology could be used in fuel cells and would
maybe even be better than what is out there already.
So, we did some work on that, and wrote a proposal for it.
We got an SBIR to start down that road, and that gave us the
diversity and the time to say, “Okay. If we can do fuel cells,
what else can we do with the material?”
Well then we tried encapsulating nanocrystals because we
knew from work that Steve and Dave [Carroll, one of the
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founders who subsequently left Clemson and Tetramer] had
done that our material disperses nanocrystals very uniformly.
That got us looking at things like quantum dots, which is
basically a type of light source.
So, we are using the same technology, but we have found
many different uses for it.
Interviewer
It seems like you have a very versatile technology, but is that
unusual? I mean, was the start of your company unusual
compared to others?
Earl Wagener
Let me put it to you this way. The fact that we had four
faculty members and me with the industrial background
really helped. I knew where value was, but I was not sure if
the material would work or not.
The luck came when we actually ran the experiments, and
the material started dispersing things extremely well. So,
you make your own luck. I mean, we could not just take the
same stuff and just throw it out there. We had to modify
it, and the stuff we are doing now is much more modified
than what we started with, but again, it is the same polymer
technology.
Interviewer
Did you originally begin with a business plan; did you write
one?
Earl Wagener
Yes, we did have a business plan, but ours was much simpler
than the business plans Caron [St. John, Director of the
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Spiro Institute for Entrepreneurial Leadership] writes and
the ones you will have to write. The model I used was a fourbox business plan that I took from Dow.
The first box included market attractiveness, both internal
and external. If there is enough market attractiveness, you
assess your competitive advantage. You have to determine
if your competitive advantage is based on patents, costs,
performance, etc. This makes you ask yourself “if I sell this
around the world, am I going to be okay?”
If you are still going strong after those two boxes, then
you come to the box for your strategy. How are you now
going to take this competitive advantage and the other
information you have and then make something of value for
the customer? Which customers are you going to choose and
why? You have to have about three or four customers to start
off with; you really cannot sell to 50 customers, so you have
to examine how to go about that.
Finally, there is the financial impact part of the business
plan. What does your pro forma look like? If you have this
hockey stick curve, how do you think that you will be selling
six times what you are making today in five years? You have
to re-evaluat all of these boxes while making the plan.
Interviewer
Did you come from educational cultures that embraced
commercialization? How is that relative to Clemson’s culture
for commercialization? Does Clemson University inhibit or
encourage entrepreneurship?
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Earl Wagener
Now, Clemson wants to be much more entrepreneurial than
it has ever been in the past, and it is trying to do this by
hiring knowledgeable entrepreneurs like Bill [Gartner].
However, the Clemson of five or ten years ago absolutely did
not encourage entrepreneurial activity. They threw stuff out
here and there and granted a few patents, but the faculty was
certainly not rewarded for trying to become capitalists of any
type. Doing so was viewed as negative.
I hope that what we are doing with this company, though,
will give back to Clemson. My Clemson roots go very deep
because when my father died, my mother had to raise three
boys all by herself. So, the town of Clemson ended up raising
us a bit, too, because she barely made enough money on her
own.
The town and the university gave us a tremendous kick
forward, and all three of us wound up with PhDs somehow.
We are giving back right now through this company, and
I hope that what we are doing can become an example for
others. Clemson’s entrepreneurial activity could be better,
but it is a tough road to hoe.
I hope that there are more people who will stand up and
encourage others to try this sort of thing and let them know
that there is help out there to do it. People like Caron St.
John, Dave Bodde, and Bill are working on the system to try
and make it better.
The younger faculty, these 26- and 28-year olds, who are
coming in now are asking, “What can I do? Can I do
something? Can I start a business?” because that is the
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paradigm in other universities, which tell their faculty to go
ahead and try such ventures.
Steve Foulger
Well, when we all arrived, Dennis, John, and I, we really
did not come from this type of culture, per se. It was a
personality trait or dysfunction that we all have that made us
come together.
We have this kind of commercialist attitude, but I did
not initially think it would be of any use at Clemson. I
honestly thought that Clemson was a village university
where research was a hobby and that there was no aspect for
commercialization. When I first got here, I did not think I
would stay longer than a year, but I was proven wrong.
I got caught in the telecom crash in 1999 when I came on
board, and it was a rough road to do anything with the
company. In fact, I pretty much stayed outside of active work
with the company early on. I got smacked a number of times
from the college for being too active in terms of patenting
things. I had a number of patents coming in, and I was still
patenting, but I really got nailed at the Dean-level for a lot of
the interactions I had with the company, and I was basically
told to back off, even though I was within the letter of the
law.
So, I stepped back at that time, but the culture has changed
quite a bit since then. However, at one point, we had a
number of really interesting comments about how running a
company as a university professor is sort of a grey area, even
though it is perfectly legal.

164 TETRAMER

For the university, it sounds great when they are having
news meetings or talking to administrators about what the
university is doing for startups, but behind closed doors, they
are looking at you and saying, “Why are you making money?”
or “Why do you have these commercial interests?” They
pretty much said that because we were professors, we should
not being doing that kind of work.
Interviewer
When you are trying to develop new things are you
motivated by your scientific curiosity or by your
entrepreneurial goals?
Steven Foulger
It has changed since then, but it was rough at first.
Earl Wagener
A good friend of mine went to Purdue in 1994, and I like
to compare them with Clemson because Purdue is 100
miles from Indianapolis and 100 miles from Chicago. They
are pretty much in the middle of nowhere like us, but they
have much more support for commercial interests because
they were able to align the governor, the president of the
university, and the tech transfer office.
They now have 105 companies in their little “village,” which
are generating a huge number of jobs, and they realized that
allowing such businesses is a good deal because they are the
source of roughly 18 % of the grants that the faculty get.
Interviewer
You talked about your competitive advantage and how you
compete resource-wise with bigger companies. Do you have
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a certain process that sets you apart from your competitors,
or is it the material?
Earl Wagener
It is the material that sets us apart because its molecular
architecture is better suited to do certain jobs than other
materials that are currently out there. For example, it
is better at generating electricity in a fuel cell than the
competitors’ materials.
Steve Foulger
Well, most of us are extremely aggressive people. Yes, we are
technically trained, and all of us did extremely well in school
and moved very quickly.
We are not the introvert types of people, and it was just our
personality traits that really made us come together. We all
had very similar personalities and thus similar goals.
Interviewer
In expanding the company are you trying to use the same
products and use them in more ways, or are you trying to
improve the product? For example, if someone else comes
out with something that is better than your product, are you
working on being able to make up for that or develop things
that are better than your competitors’ products?
Earl Wagener
Both. Whenever you are selling something, in most cases you
will have a three bottle approach. I will use a commercial
example of shampoo ingredients, which I dealt with at
Stepan. Let us say that L’Oreal currently has a shampoo
product (bottle #1), but Procter and Gamble also has a
shampoo (bottle #2) that has better performance than
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L’Oreal’s, putting L’Oreal at a commercial disadvantage.
L’Oreal would come to us at Stepan and say “if you
will develop a superior performing shampoo (bottle #3)
to Procter’s (bottle #2), we will agree to buy all of our
ingredients from Stepan.
Our job then was to analyze bottles #1 and #2 and come up
with bottle #3, which would outperform both. In some cases
if bottle #3 just equaled Procter’s bottle #2 but was lower
cost, we got the business.
In essence, commercializing new technology is making bottle
#3 products. And then you basically put technology together
and try to improve it. In these situations, communication
with the customer is the most important thing because they
have to tell you what their pain points are. They always want
you to lower your costs, but in the game we play, we have
to consider both performance and cost. Because our cost
is large compared to other materials, there is no way that
we can compete with polycarbonates in terms of just cost.
Polycarbonates are maybe $2.00 per kilo, and our material
is $10,000 per kilo, so we clearly have to have superior
performance.
We are also inventing and innovating new materials. We
keep investigating what else we can do with the same
material. The way we do that is by contacting companies and
telling them that we think our product can meet their needs,
just like we did with GM. Right now we are going through
that process in the area of coating glass fibers.
Interviewer
Do you have a marketing department?
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Earl Wagener
No, not yet, but we will need one sometime. We cannot
afford marketing right now. Until we have the money to pay
someone a salary, we will just have to do some of the nontechnology-related stuff, like marketing ourselves. In terms
of the marketing side, our faculty owners do an excellent job
because this is a highly technical content product. When
they go out and give fundamental academic seminars, they
are essentially selling our technical competitive advantages.
Since they know this technology well, they are very successful
at selling it. It is really a win/win situation because they get
recognition and grants for doing something really unusual,
which then makes their product more sellable.
Interviewer
What’s your miss rate, and how does that impact your future
projects?
Earl Wagener
Well, in the optical area our miss rate was very high to begin
with. We sent a lot of samples out, but people did not call
us back, or we had to have people who could manipulate the
material in particular ways that we could not do ourselves.
So, we had to send it out to them and have them do it, but
they did not always do the right thing, so there were a lot of
misses there.
Early on our miss rate was probably around 80%, but now,
I would say that we have a miss rate of 20-25% percent. We
are hitting pretty well right now.
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